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Introduction 
Drug misuse is a serious threat to the security of the prison system, the health of individual prisoners 
and the safety of prisoners and staff. Its effects ripple outwards to harm prisoners’ friends and 
families and the wider community of which they are a part. An increasing number of reports of the 
misuse of medication in prison and concerns that traditional supply reduction and treatment 
strategies were ineffective were the initial driver for this thematic inspection. However, the 
availability of new psychoactive substances (NPS), particularly synthetic cannabis known as ‘Spice’ or 
‘Mamba’, became highly prevalent during the preparation for this report. NPS have created significant 
additional harm and are now the most serious threat to the safety and security of the prison system 
that our inspections identify.  
 
This thematic inspection examined the changing extent and patterns of drug misuse in adult prisons 
and assessed the effectiveness of the response to it. The inspection’s remit did not include tobacco 
and alcohol use by prisoners, which are important issues in their own right and raise significant 
operational and policy challenges. Of course, there are wider questions to be asked about the legal 
status of drugs in the community and the historical inconsistency of legal responses to various 
harmful substances. This report does not address those issues. There is no prospect of any 
relaxation of the rules governing the substances that are permitted in prisons and so there is an 
urgent requirement to address the harm that substance misuse causes in prisons in that realistic 
context. 
 
The report draws on the evidence of 61 adult prison inspections published between April 2014 and 
August 2015, the 10,702 survey responses from individual prisoners that were collected as part of 
those inspections, and detailed field work that was conducted in eight prisons between June and 
November 2014. We spoke to prisoners, prison staff and managers, drugs and health workers, and 
other experts. We reviewed a wide range of research undertaken by other bodies. We also 
considered some earlier inspection findings, where relevant. The inspection was carried out by the 
inspectorate’s research team and specialist health and drugs inspectors. 
 
Changing patterns of drug use in the community provide a useful context for understanding drug 
misuse in prisons. It is impossible to know for certain the extent and type of drug misuse in the 
community or in prisons. Nevertheless, there is a wealth of evidence to suggest that patterns of drug 
use are changing in the community, with drug use appearing to be reducing. The 2014–15 Crime 
Survey for England and Wales found that 8–9% of adults reported illicit drug use over the previous 
year, down from 12% in 2003–04. Cannabis remains the most widely used drug and there has been a 
well-evidenced decline in illicit opiate use. The reported use of prescribed medication and NPS in the 
community is at a relatively low level. Patterns of dug misuse vary with age, gender, geography and 
lifestyle.   
 
There are important differences between drug misuse in prisons and the community. A declining 
number of prisoners needing treatment for opiate misuse reflects trends in the community, although 
many of those requiring opiate treatment in prison have complex dependence, social, physical and 
mental health issues. Prisoners are more likely to use depressants than stimulants to counter the 
boredom and stress of prison life. The use of synthetic cannabis and diverted medication reflects a 
response to comparative weaknesses in security measures. Often, the price of drugs is higher and the 
quality poorer in prison, reflecting greater difficulty of supply. The combination of community 
influences, prisoner demographics and individual prison contexts means that the patterns of drug use 
will differ from prison to prison. As this report was being prepared, there was an acceleration in the 
use and availability of NPS. It is important to understand, however, that success in combating current 
challenges in prisons, such as the availability of NPS or specific medications, will lead to an increased 
demand for other drugs, and to be prepared for this.  
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At the present time, some synthetic cannabis is legal (depending on its exact composition) to possess 
in the community but all forms are banned in prisons. This has four consequences. First, it is cheap to 
buy or manufacture in large quantities in the community. Second, the difference between the price in 
the community and that in prison is much greater than for drugs such as opiates or cannabis, which 
are illegal in both settings. Third, despite the high mark-up, it is still relatively cheap in prisons. 
Fourth, current testing methods cannot detect synthetic cannabis, and its composition may change 
from batch to batch. New tests are being developed and special drug dogs are being trained to 
identify it, but neither of these measures are yet available in most prisons. This means that the risks 
involved in supply are low and large profits can be made by supplying it in bulk. The low ‘wholesale’ 
price, high profit margin and ready supply means that profits can be maintained even if considerable 
amounts are intercepted. Low risks, high profits and large-scale supply mean that distribution to and 
within prisons may be linked to organised crime. Payments can be made and collected, and debts 
enforced in the community. Banning harmful NPS in the community would reduce the price 
differentials, and hence profits. Changes to the legal status of NPS, the urgent development and 
implementation of better testing and detection methods, effective joint work with law enforcement 
agencies, and the imposition of clearer disciplinary and categorisation consequences would increase 
the risks of supply, and hence decrease its attractiveness.  
 
Diverted medication is popular among adult prisoners and can come from medication prescribed in 
the prison or be smuggled in. Prisoners may sell or misuse medication because they feel they cannot 
legitimately get the medication they need, to mimic the effects of illegal drugs or to trade. Effective 
prescribing practice and drug administration are necessary to prevent this, along with the 
development of less harmful therapeutic alternatives for legitimate health concerns. 
 
No one should be in any doubt about the harm that drug misuse does in prisons. It damages 
prisoners’ health and sometimes causes deaths. The health consequences of synthetic cannabis use 
have been particularly severe because of its inconsistent composition and unknown effects. Some 
prisons have required so many ambulance attendances that community resources were depleted. In 
at least one prison, ambulances are known as ‘mambulances’. The Prisons and Probation 
Ombudsman found that, in 19 deaths in prison between April 2012 and September 2014, the 
prisoner was known, or strongly suspected, to have been using NPS-type drugs before their deaths. 
We have had credible accounts of prisoners being used as so-called ‘spice-pigs’ to test new batches 
of drugs. In some cases, this was in return for free samples; in others, vulnerable prisoners were 
tricked or coerced into sampling the batch. Debt associated with synthetic cannabis use sometimes 
leads to violence and prisoners seeking refuge in the segregation unit or refusing to leave their cells. 
Debts are sometimes enforced on prisoners’ friends or cell mates in prison, or their friends and 
families outside. Drug misuse damages rehabilitation and, if efforts to reduce reoffending are 
unsuccessful, creates more victims. Profits from drug supply may be used to fund organised criminal 
activity in the community. 
 
Illegal drugs, NPS and illicit medications may get into prisons in a number of ways. The nature of the 
issue means that it is not possible to quantify this, and supply routes are likely to differ from prison 
to prison. In large training prisons, with long perimeters and relatively free prisoner movement, drugs 
may be thrown into the prison in small packages (in a tennis ball, for instance), in larger packages 
fired by catapults or, in some recent cases, dropped by drones. Easy access to illicit mobile 
telephones makes it possible to plan the drops carefully. In a busy local prison, drugs may come in 
with prisoners moving back and forth to court. Some prisoners may get themselves recalled, for a 
price, and smuggle in drugs hidden in body cavities. The wide variety of staff working in prisons – 
officers, medical professionals, trainers and suppliers, for instance – may bring drugs in or facilitate 
other forms of access. Drugs come in with visitors – sometimes willingly and sometimes under 
pressure. Drugs may also come in with prison goods or prisoner packages and correspondence. 
Synthetic cannabis can be sprayed onto paper and smoked, making it extremely difficult to detect.  
 
The needs of security should be balanced with the needs to allow prisoners to undertake the 
activities, and have the family relationships, necessary to reduce the risk that they reoffend. 
Nevertheless, testing and searching processes should be carried out rigorously to reduce the supply 
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of traditional drugs. Mandatory drug testing (MDT) is traditionally used as a measure of a prison’s 
performance in reducing drug supply; however, MDT will not detect synthetic cannabis or most illicit 
medication and is no longer a useful performance indicator.  
 
Reducing supply is only one part of a successful strategy to respond to drug misuse in prison. 
Individual prisons need a whole-prison response to drug misuse based on a thorough needs analysis. 
A whole-prison approach will include measures to reduce supply and measures to reduce demand 
through effective treatment, psychosocial support and education. Strategies should coordinate the 
activities of different departments and services in the prison and in the community. The strategy 
needs to go beyond specific drug services to reducing demands for drugs by offering attractive 
purposeful alternatives, reducing prison violence and creating positive staff–prisoner relationships.  
 
The strategy should include effective treatment and psychosocial support. The development of 
evidence-based treatment and support strategies has been significant and provides a model for policy 
development that should inform responses to current needs. Individualised treatment and the growth 
of peer-led support processes have been successful, although implementation is sometimes 
inconsistent. New approaches should be used to engage prisoners misusing synthetic cannabis who 
may not see a need to work with drug services in the same way as users of more traditional drugs. 
Risks of inconsistent treatment between England and Wales of prisoners who are dependent on illicit 
opiates need to be addressed. Prisoners in Wales who are opiate dependent do not receive first 
night opiate substitution treatment, unlike their counterparts in English prisons, which creates 
considerable risk and means that prisoners moving between prisons in the two nations will not have 
consistent treatment or support.  
 
Education and information from credible sources have an important role to play in reducing drug 
misuse, particularly use of synthetic cannabis. The National Offender Management Service (NOMS) 
and individual prisons have produced a wide range of good education and information material. We 
have seen examples in some prisons of reported synthetic cannabis use reducing after the 
introduction of prisoner-led sessions using effective resources in the induction of new arrivals. 
Prisoners’ families may be a source of supply, a resource or themselves victims of the consequences 
of drug misuse. Education and information should be directed at them and, where appropriate, the 
prison should work with families to address prisoners’ drug misuse. Confidential assistance should be 
available to friends and family members who may be pressured to supply drugs or pay drug debts, or 
who may be worried about the misuse of drugs by a family member or friend in prison. 
 
NOMS has made considerable efforts to reduce the supply of and demand for drugs in prisons. New 
legislation is being introduced; detection of NPS is being improved by the introduction of new tests 
and the training of drug dogs. The variable composition of each batch of NPS has made the 
development of an effective test extremely complex and challenging. Joint work with health 
commissioners and providers is being undertaken to extend access to recovery services as part of 
prisoners’ rehabilitation and improve continuity of treatment and support on release. Despite these 
efforts, the Prison Service and other relevant national bodies have found it difficult to keep pace with 
and respond to the unprecedented and rapid growth of NPS use in adult male prisons. It has 
sometimes been difficult to make best use of the information available from individual establishments 
and other sources to identify changing needs and modify the strategy accordingly. In part, this reflects 
a too-willing acceptance in some establishments that drug misuse is an inevitable part of prison life 
and cannot be reduced. It has taken time to develop new drug tests, change legislation and develop 
new resources. These measures are still not in place and their effectiveness has not yet been fully 
tested on a national scale. This report proposes the establishment of a national committee, chaired 
by the Prisons Minister, so that it has the authority to bring together cross-government and cross-
sector expertise, to assess changing needs and ensure that the national strategy adapts and responds 
accordingly.  
 
The emergence of NPS as the main drug of choice in adult male prisons is just the most recent 
change in a long history of drug misuse in prisons. As responses to this new challenge become more 
effective, new substances or types of use will emerge to replace it. Drug misuse, of whatever type, 
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does serious harm in prisons and in the wider community. Lessons should be learnt from the 
emergence of NPS at a national and local level to ensure that a dynamic, responsive and well-
coordinated whole-system and whole-prison strategy is in place, both to reduce the harm of current 
use and respond effectively to future needs. 
 
 
 
Nick Hardwick December 2015 
HM Chief Inspector of Prisons 
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Section 1. Summary 
The issue 
1.1 This thematic inspection examined drug misuse in prisons. Tackling drug misuse is a key 
priority for the Prison Service. Drug misuse in prisons damages the health of individual 
prisoners, undermines the security and safety of prisons, and hampers rehabilitation. 
Prisoners are more likely than the general population to have histories of drug misuse, and in 
some cases this misuse continues in prison. When work on this inspection began, there had 
been a recognised shift away from the use of opiates and Class A drugs towards the misuse 
of medication in prisons. During the course of this work, patterns of substance misuse in 
prison changed again and the use of new psychoactive substances (NPS), and in particular 
synthetic cannabis, has emerged as a major problem. This thematic inspection aimed to 
examine changing patterns of substance misuse in adult prisons, assess the effectiveness of 
current policy and operational responses, and suggest how they might be improved. 
Methodology 
1.2 This report drew on 61 HM Inspectorate of Prisons (HMI Prisons) inspection reports 
published between April 2014 and August 2015. A total of 10,702 survey responses were 
included in the analysis. These inspection findings were supplemented with findings from 
additional fieldwork conducted in eight prisons between June and November 2014.  
1.3 The additional fieldwork comprised a confidential survey which asked prisoners about their 
drug use before going into custody, and also within their current prison, and a total of 1,218 
surveys were completed by prisoners in these eight prisons. Qualitative interviews were also 
undertaken with prisoners, to explore further their drug use both before and during 
custody. Interviews also explored their experiences of prison-based drug treatment. Within 
the eight prisons, interviews were also conducted with staff involved in supply reduction and 
treatment, concerning trends of, and motivation for, drug misuse in the community and in 
the prison, and the support available. In addition, interviews were conducted with 
commissioners of community and prison drug treatment services in England. Further detail 
about HMI Prisons’ inspection processes and the specific methodology used for this 
fieldwork can be found in Appendix I. 
1.4 Third-party research was used to provide background and context for the report. Sources 
are acknowledged in the text. 
1.5 The inspection was undertaken by HMI Prisons, with support and advice where required 
from other inspectorates: HMI Probation, HMI Constabulary, the Care Quality Commission 
(CQC) and Healthcare Inspectorate Wales (HIW). We are grateful for their assistance. 
Key findings 
1.6 Substance misuse is a serious threat to the security of individual prisons, the 
health of prisoners and the safety of prisoners and staff. Crime associated with 
the supply of drugs to prisons and the negative impact of drug use on measures 
to reduce reoffending adversely affects the community as a whole.  
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Throughout this report, we describe the adverse consequences of substance misuse in 
prisons. Crime and disorder associated with the supply and distribution of illicit substances in 
prisons undermines effective security in individual prisons. Substance misuse damages the 
health of prisoners and in some cases leads to death. Violence and disorder associated with 
substance misuse affects the safety of prisoners and staff. The involvement of organised crime 
in the supply of drugs to prisons may lead to pressure on prisoners’ families and friends, and 
have wider effects on the community as a whole. Some prisoners report that they have 
developed a drug problem in prison, and drug use undermines measures to rehabilitate them 
and reduce reoffending (see paragraphs 2.28 to 2.30 and 3.34 to 3.54). 
1.7 Patterns of drug use are changing in the community and, although this will be 
reflected in patterns of drug use by prisoners both before and, to some extent, 
within custody, there are some important differences between drug misuse in 
the community and in prison.  
It is impossible to be certain about the extent and nature of drug misuse in either the 
community or prisons. The 2014–15 Crime Survey for England and Wales found that, for 
each of the last five years, between 8% and 9% of adults reported using an illegal drug in the 
previous year, down from 12% in 2003–04. Cannabis is the most common drug used in the 
community. There has been a long-term decline in illicit opiate use. Reported use of new 
psychoactive substances and misuse of prescribed medication are low. Patterns of drug use in 
the community vary by age, gender, region and lifestyle. Offenders are more likely than the 
general population to misuse drugs and prisoners report high use of illegal drugs before their 
imprisonment. Drug use in prisons will, to some extent, reflect use in the community but 
there are some important differences. There is a preference for depressants, rather than 
stimulants, in prisons. Security measures affect the choice and quality of what is available. The 
misuse of opiates in prisons appears to be declining but remains an important issue. There 
has been an increase in the use of diverted medication. Large numbers of prisoners present 
with chronic pain, and some come into prison taking, or are started in prison on, 
inappropriately prescribed drugs. In recent years, the use of NPS – in particular, synthetic 
cannabis, known as ‘Spice’ or ‘Mamba’ – has grown significantly (see paragraphs 2.2 to 2.22 
and 3.1 to 3.47). 
1.8 NPS – specifically, synthetic cannabis – are a problem in many prisons and a very 
serious threat to the safety and security of some.  
Synthetic cannabis use has spread to most prisons and has destabilised the safety and security 
of some we have inspected. Synthetic cannabis has caused or is still causing wide-ranging 
problems, including medical emergencies, deaths, bullying, violence and debt. The extent of 
the problems and level of use appears most severe in category C establishments. There is the 
potential for large profits to be made from synthetic cannabis, and this has led to gangs and 
organised crime becoming involved in the distribution in some prisons (see paragraphs 3.26 
to 3.32 and 3.48 to 3.54). 
1.9 Every prison does not have the same drug problem(s), and patterns of use may 
change quickly. Policy and operational responses should be flexible and dynamic 
to meet changing patterns of use.  
The extent and the nature of illicit drug misuse vary between individual establishments and 
can even be different in different parts of the same establishment. Synthetic cannabis is not 
the only drug issue facing prisons in England and Wales, and its use varies in different prisons. 
Patterns of use change rapidly at both a national and individual level. The problems associated 
with synthetic cannabis can be very obvious and have a clear adverse effect on some prisons, 
but most prisons have wider-ranging drug issues, including illicitly brewed alcohol, traditional 
drugs (including cannabis and opiates) and illicit medication. Successful measures to reduce 
the supply of synthetic cannabis are likely to increase demand for other substances. Policy 
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and operational responses have not been sufficiently flexible and dynamic to meet these 
changing and varied patterns of use (see paragraphs 3.1 to 3.54, 4.1 to 4.36 and 4.51 to 4.56). 
1.10 The development of a coordinated response to synthetic cannabis has not kept 
pace with the rapidly increasing use of synthetic cannabis in adult male prisons.  
The prevalence of NPS has been increasing in the UK since 2008. We first identified 
synthetic cannabis as an issue in a prison in 2011, but in our annual report for 2013–14 we 
were already reporting that its use had become widespread in adult male prisons. National 
developments, such as new legislation, new drug tests and dogs trained to detect synthetic 
cannabis, are now being established. We observed pockets of good practice develop within 
individual prisons and by specific treatment providers, but national prison guidance only 
emerged in 2015, which has resulted in some inconsistent and inadequate approaches across 
the estate (see paragraphs 3.26 to 3.32, 4.3 and 4.26 to 4.28). 
1.11 Current testing methods are inadequate to discourage use or provide an 
accurate assessment of use on which local and national responses can be based.  
There are no effective testing methods for synthetic cannabis available nationally at present, 
although some are in development. Assessments of local needs are currently hindered by 
inadequacies in the present mandatory drug testing (MDT) system. MDT is a useful supply 
reduction strategy but some illicit drugs, such as synthetic cannabis, are popular in prisons 
simply because they do not show up in current drug tests. This makes MDT results an 
inaccurate measure of drug misuse in prisons and an inappropriate measure of prison 
performance (see paragraphs 4.3, 4.18 and 4.29 to 4.31). 
1.12 Few establishments have the necessary ‘whole-prison’ approach to addressing 
illicit drug use.  
Drugs have the potential to affect all areas of prison life and, similarly, all aspects of prison 
life have the potential to influence the demand for dugs. A ‘whole-prison’ approach is 
necessary which tackles:  
 Supply reduction: stopping drugs getting into the prison.  
 Demand reduction: reducing the demand for drugs by addressing wider issues that may 
lead to drug use in prison and on release.  
 Effective treatment for drug and alcohol issues, including harm reduction.  
A prison’s drugs and alcohol strategy needs to be embedded into every department, with 
effective structures to coordinate activity across the prison. Strategies and treatment should 
not just focus on drugs. Effective drug treatment also needs to address the wider issues that 
affect drug use, including adequate purposeful activity, and to include joint working between 
agencies and prison departments to address all the wider issues, including housing, 
employment, physical health and mental health. Poor performance in these areas in some 
prisons undermines effective treatment (see paragraphs 4.1 to 4.103). 
1.13 Efforts to reduce the supply of drugs are too variable across the prison estate. In 
some cases, this is exacerbated by a shortage of suitable resources.  
The strategies to detect illicit NPS and medication distribution and misuse are broadly the 
same as for other drugs. Some prisons are more effective than others at reducing supply, and 
in some cases a lack of suitable resources, such as a lack of trained drug dogs or sufficient 
staffing to carry out necessary testing or searches, contributes to inadequate responses (see 
paragraphs 4.19 to 4.28). 
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1.14 Prison-based drug treatment services have improved dramatically in England 
over the past 10 years.  
The introduction of evidence-based and individualised treatment and support services, such 
as counselling, assessment, referral, advice and throughcare (CARAT) and the integrated 
drug treatment system (IDTS), and the subsequent developments in commissioning and 
provision have greatly improved drug treatment in English prisons and the community for 
offenders with opiate dependence. However, prisoner outcomes are adversely affected in 
some prisons by various factors, including poor prescribing; infrequent reviews; an 
insufficient range, quantity or quality of psychosocial support; and inadequate integration 
between services and departments. Community and prison drug services need to be 
innovative to make their services attractive to, and relevant for, people who use drugs other 
than opiates (see paragraphs 4.57 to 4.103). 
1.15 The lack of IDTS in Wales leads to poorer outcomes for some prisoners and 
creates inconsistency in substance misuse treatment between prisons in England 
and Wales.  
IDTS is not available in Welsh prisons. Our inspection findings have demonstrated that large 
numbers of prisoners in Wales have drug and alcohol problems on arrival in prison. Unlike 
their counterparts in English prisons, prisoners in Wales who are dependent on illicit opiates 
do not receive first night opiate substitution treatment. Instead, they are generally offered 
symptom relief only, which increases the risk of physical and mental distress in prison and of 
accidental overdose on release if they return to illicit drug use. In our inspections of Welsh 
prisons, we have found that those who arrive in prison on confirmed prescribing of opiate 
substitution treatment in the community will have this prescribing continued in prison, 
although the length of time for which the prescribing will be continued and the level of 
psychosocial support available vary between the prisons. This lack of consistent, coordinated, 
evidence-based treatment, including access to opiate substitution prescribing on arrival, has 
led to poorer outcomes for some prisoners. Many Welsh residents are held in English 
prisons and receive IDTS treatment which would not be available if they moved to Welsh 
prisons. The new North Wales prison which is being built in Wrexham, will hold large 
numbers of English prisoners. The drug treatment system in prisons needs to be the same 
across the estate and equivalent to that in the community (see ‘Drug misuse and treatment 
in Wales’ section on page 61). 
1.16 Insufficient use is made of prisoners’ families, friends and prisoner peer 
supporters to reduce supply and demand for illicit substances.  
Well-trained and supervised peer supporters contribute to improved outcomes for 
prisoners. High-quality, properly supervised peer-led social, emotional and information 
support is key to effective drug treatment. Too many prisons do not do this effectively. 
Family and friends are also a largely untapped but key resource for substance misuse 
recovery in prisons. Research, our recent resettlement thematic report and interviews with 
prisoners for this thematic inspection confirm that an offender’s family and friends are critical 
to their successful rehabilitation, including from addiction and into recovery. Families and 
friends may also be a negative factor and, willingly or through coercion, be a source of 
supply. Targeting families and friends for education and support is essential to improving 
outcomes for individual prisoners and to reducing supply. Too few prison drug treatment 
services do this effectively (see paragraphs 4.28 to 4.86). 
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Recommendation       To Ministers  
1.17 The Prison Service should improve its response to current levels and types of 
drug misuse in prisons and ensure that its structures enable it to respond quickly 
and flexibly to the next trend. A national committee should be established, 
chaired by the Prisons Minister, with a membership of relevant operational 
experts from the public and private prison sectors, health services, law 
enforcement, substance misuse services and other relevant experts. The 
committee should be tasked to produce and publish an annual assessment of all 
aspects of drug use in prisons, based on all the available evidence and 
intelligence, and produce and keep under review a national prison drugs 
strategy.  
Recommendations      To NOMS 
1.18 Individual prisons should have an up-to-date drug and alcohol strategy and action 
plan which includes supply reduction, demand reduction and treatment based on 
a comprehensive local assessment of need, overseen by a committee which 
includes consistent attendance from all departments and relevant community 
representation. Resources should be allocated to ensure that the required 
actions, including training, drug testing and searching, occur promptly.   
1.19 Work should be carried out to:  
 Provide education and information for families and visitors about synthetic 
cannabis and other forms of illicit drug use 
 Develop clear protocols for the involvement of families, where appropriate, 
in work with individual prisoners to reduce the harm caused by substance 
misuse 
 Provide and widely advertise a national, independent hotline that enables 
family members to report and seek assistance with threats related to the 
supply of illicit drugs and concerns about a prisoner’s use. 
1.20 It should be ensured that protocols with the police at national and local level 
establish effective actions to disrupt the supply of illicit substances by visitors, 
prisoners, staff and other sources. 
1.21 Mandatory drug testing results should not be used as a measure of prison 
performance.  
1.22 Prisoners should have a consistent range of purposeful activity throughout the 
week and at weekends.  
Recommendation     To Ministers and NOMS 
1.23 Urgent action should be taken to reduce the harm caused by new psychoactive 
substances (NPS), particularly synthetic cannabis. This should include: 
a)  Measures to reduce the attractiveness and profits of supply by: 
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 Quickly introducing legislation that takes due account of the advice 
from the Advisory Council on the Misuse of Drugs, bans harmful 
psychoactive substances and so reduces the attractiveness of supply 
 Urgently developing and rolling out more effective testing methods 
 Regarding the persistent or large-scale supply of NPS as a security 
threat and recategorising the prisoners involved accordingly. 
b) The development by every prison of a peer-led programme of substance 
misuse education, with effective resources to educate prisoners, particularly 
new arrivals, about the dangers and other consequences of synthetic 
cannabis use. 
c) The development and delivery of national resources to ensure that all staff 
in prisoner contact roles are trained to understand the symptoms and 
consequences of synthetic cannabis use and that they are aware of how to 
deal with it.  
Recommendation  To Welsh Assembly Ministers and NOMS 
1.24 Prisoners in England and Wales should have consistent access to equivalent 
substance misuse treatment. 
Recommendation      To NHS England 
1.25 Commissioning arrangement should ensure that drug treatment and 
psychosocial services provide a comprehensive range of interventions that 
consistently meet current standards but encourage and develop innovative 
practice. Services should be individualised; well integrated with the prison, health 
services and community support; appropriate to the needs of the population; and 
include effective peer support, family support and services for NPS and illicit 
medication.  
Recommendation  To NHS England and Public Health England 
1.26 A cohesive national strategy to reduce the misuse of prescription and over-the-
counter medication should be developed which includes: 
a)  Monitoring of prescribing trends in the community and prisons, challenging 
prescribing that is outside normal ranges and the sharing of information on 
emerging trends locally and nationally. 
b)  Prompt access for prisoners to cohesive pain management services which 
include appropriate non-pharmacological and pharmacological options. 
c)  Evidence-based clinical and psychosocial treatment for dependence on illicit 
medication. 
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Section 2. Background to the report 
2.1 The focus of this thematic study is substance misuse in adult prisons in England and Wales. 
However, it is necessary to place this in the context of substance misuse and treatment 
within the wider community as prisoners come from, and will return to, the community on 
release. 
Changing patterns of substance misuse within the general 
population 
2.2 Illicit drug misuse is a largely hidden or secret activity, which means that accurate 
information about its prevalence is difficult to obtain. Data about illicit drug use among the 
general population can be obtained from several sources, each with its own limitations, 
including drug treatment statistics, crime statistics, drug-related deaths and research. For 
example, the Crime Survey for England and Wales (CSEW)1 relies on self-reported drug use, 
which cannot be verified objectively, and it does not cover those living in group residences 
(including university halls of residence) or the homeless, where there is a higher level of drug 
use. In addition, the time lag between data collection and the publication of research2 means 
that it is impossible to maintain a completely accurate picture of a rapidly changing situation, 
and much available research is dated. However, the CSEW gives useful information on crime 
trends, including drug misuse, which can be compared over time. 
Drug use in England and Wales 
2.3 According to the latest CSEW (Home Office, 2015), covering the period April 2014 to 
March 2015, over a third of adults (34.7%; 11.3 million) have used an illicit drug at some 
point in their life (lifetime use). For each of the last five years, 8–9% of adults have reported 
using an illicit drug in the previous year, following a gradual reduction from a peak of 12% in 
2003–04. Of those who reported illicit drug use in the previous year, over a third of adults 
(38%) said that they had taken drugs only once or twice in that year, but 36% reported 
having used drugs more than once a month and 8% of the total reported daily use. Those 
who reported taking drugs daily were most likely to be taking illicit tranquilisers (13%) or 
cannabis (9%).   
2.4 Cannabis is by far the most used illicit drug in England and Wales. CSEW findings suggest 
that the proportion of adults reporting cannabis use in the previous year has remained 
stable, at between 6% and 7%, since 2009–10. Powder cocaine was the next most used drug 
in 2014–15 among adults (2.3%), followed by ecstasy (1.7%). Only 3.2% of adults (just over a 
million) had taken a Class A drug in the previous year, which has also been broadly stable in 
recent years.  
2.5 There has been a long-term decline in illicit opiate use, attributed to several factors, including 
criminal justice initiatives to disrupt supply chains, changing demographics and fashions, and 
the positive impact of an investment in treatment. An increase in the use of injected image- 
and performance-enhancing drugs such as steroids has been reported recently, although the 
 
1 The CSEW (previously known as the British Crime Survey) is an annual survey which has been running since 1982. It asks 
around 35,000 adults and 3,000 children aged 10–15 years, resident in households in England and Wales, about their 
experience of a range of crimes during the last year. 
2 The fieldwork for the CSEW takes place over a 12-month period, which means that some data are a minimum of 12 
months ‘out of date’ at the point of publication. 
 Section 2. Background to the report 
18 Changing patterns of substance misuse in adult prisons and service responses 
                                                                                                                                                                                    
full extent of the problem is unknown. Since 2003–04, the percentage of primary cannabis 
presentations at drug treatment services has steadily increased, from 10.7% of all 
presentations to 26.8% in 2013 (UK Focal Point, 2014). 
2.6 Opiate users are over-represented in drug treatment, primarily because opiate substitute 
prescribing encourages them into treatment; however, the numbers presenting for, and in, 
treatment for heroin use have been reducing over recent years. Drug treatment figures for 
England and Wales (National Treatment Agency for Substance Misuse (NTA), 2014) show 
that the total number presenting for treatment fell by 16% between 2008–09 and 2013–14 
(from 84,520 to 70,930); the number presenting specifically for opiate or crack cocaine use 
fell by 20% (from 58,016 to 46,001) in the same period. However, it is estimated that only 
one in eight high-risk drug users (heroin and crack) in the UK (excluding Northern Ireland) is 
actually in treatment (UK Focal Point, 2014). The over-40s now make up almost a third of 
the entire drug treatment population in England, and 90% of those are for heroin and/or 
crack. These older users tend to be more entrenched in their drug problems and more 
vulnerable to all the associated health and social problems, and they find it more difficult to 
recover from their dependency. 
Demographic and geographical variations according to the CSEW 
2.7 The CSEW showed that the overall use of illicit drugs has been in general decline over the 
last 20 years, and that much of the drop can be attributed to falling rates of drug use among 
young people (16–24-year-olds). It highlighted that patterns of illicit drug use are not evenly 
distributed across the population, with young people still being more likely to use illicit 
drugs, and to use them more frequently, than older people. It showed that 19.4% (1.2 
million) of young adults had used illicit drugs in the previous year and that 5.1% had used 
them at least monthly. Men are more likely than women to take drugs. Around one in eight 
adult men (11.9%) compared with one in 18 adult women (5.4%) reported taking an illicit 
drug in the previous year. 
2.8 People with a long-standing illness or disability were more likely than those without such an 
illness or disability to have misused prescription-only painkillers or to have used an illicit drug 
in the previous year. Cannabis use was a large contributor to these proportions, as 9.4% of 
people with a long-standing illness had used cannabis in the previous year, compared with 
6.3% of those without.  
2.9 Adults who reported drinking alcohol three or more days per week in the previous month 
were around twice as likely to have used an illicit drug and seven times more likely to have 
used a Class A drug in the previous year than those who reported drinking less than once a 
month. 
2.10 The level and type of drug use also vary markedly across England. For example, the highest 
rates of opioid and combined opioid and crack use were in Humber and the lowest rates in 
the East of England. The North-East had the highest injecting rate and London had twice as 
much crack use as in the lowest-use areas (Hay et al., 2014). The CSEW showed that people 
living in urban areas reported higher levels of drug use than those living in rural areas. The 
poorest local authorities tend to have the highest prevalence of problematic drug users 
(Marmot et al., 2010). A high proportion of problem drug users3 have been socially excluded 
as children and young people; many are poorly educated and a high proportion live in poor 
housing (Seddon, 2006). 
 
3 The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defines problem drug use as ‘injecting drug 
use or long duration or regular use of opioids, cocaine and/or amphetamines’. 
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Polydrug use 
2.11 The CSEW has looked at polydrug use,4 including alcohol, since 2010–11. Polydrug use 
carries a higher risk of overdose and adverse consequences. In the combined 2013–14 and 
2014–15 surveys,5 9% of respondents who had used drugs in the previous year said that they 
had used more than one drug simultaneously the last time they had used drugs. More than 
half (56%) of polydrug use involved drinking alcohol along with taking other drugs. Over a 
quarter of respondents (27%) said that they took the particular combination of drugs as they 
wanted the combined effect of more than one drug to enhance or extend the effect; others 
reported that they used one drug to cancel the effects of the other (24%) – for example, to 
‘come up’ or ‘come down’ – or that they just took whatever drugs were available or offered 
to them at the time (26%); and one in six (18%) gave no particular reason for their reported 
polydrug use. 
New psychoactive substances (NPS) in England and Wales  
2.12 There has been a reported rise in the use of NPS since 2008–09 in the UK and 
internationally (DrugScope, 2015a). The latest CSEW data indicate that the current 
prevalence of NPS use among adults is low compared with more established drugs such as 
cannabis, powder cocaine and ecstasy. Fewer than a million adults (937,000 people; 2.9%) 
had used an NPS in their lifetime and fewer than one in 100 adults (0.9%) had taken NPS in 
the previous year.6 Young male adults (aged 16–24 years) accounted for almost half of all the 
NPS users in the previous year. Herbal smoking mixtures were most commonly used, 
reported by 61% of adults who had used NPS in the previous year.  
What are NPS? 
 
NPS are predominantly, but not always, synthetic versions of existing drugs developed to avoid legal 
sanction and detection, and are easily available through retail outlets and the internet. The term 
‘legal highs’ was previously commonly used but has been replaced with the term ‘NPS’ as it gave a 
false impression of safety, and laboratory testing of alleged legal highs has shown that many contain 
illegal compounds. NPS appear and disappear rapidly under multiple brands, and users are not always 
aware of what they are taking. This makes it difficult to capture the full level of use, assess the health 
and substance misuse need, and put credible, timely information into the public domain.  
According to DrugScope (2014), NPS can be broadly divided into:  
 
 Synthetic cannabis (Black Mamba, Spice),  
 Stimulant-type drugs (BZP, mephedrone, Benzo Fury) 
 Hallucinogenics (methoxetamine, Bromo-Dragonfly). 
 
Mephedrone-style drugs and synthetic cannabis appear to be the most prevalent NPS in the UK 
(DrugScope, 2015a). Synthetic cannabis drugs are liquid chemicals that are usually sprayed onto herbs 
to indicate that they are intended to be smoked, even when sold as incense. They do not have a 
unique smell. They are stronger than traditional cannabis, with potency varying between 
preparations, and users may experience severe reactions from using too much. The liquid form is 
increasing in popularity, partly because of e-cigarettes, but it can also be sprayed onto paper (and 
used to roll cigarettes), making it more difficult to detect than herbal matter, which would raise 
suspicion even if it does not smell like cannabis (see Annex).  
                                                                                                                                                                                     
4 Polydrug use is more than one type of drug being taken either at the same time or within the same period. 
5 As numbers of polydrug and polysubstance users are small, two years of survey data have been combined for this analysis. 
6 We do not have useful trend data yet as these substances are new, as are research activities to monitor them. For 
example, the 2014–15 CSEW asked questions on the use of all NPS in the previous year, whereas previous studies had 
asked about specific NPS only. 
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The key harms associated with NPS are not completely understood as little is known about the 
pharmacology, toxicology and safety profile of these compounds in humans (European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), 2009). The potential for physical and 
psychological dependence is unclear but is assumed to be at least equivalent to that of the drugs they 
are based on.  
 
According to the Scottish Drugs Forum (2013), the key harms currently associated with NPS use 
include: 
 
 Overdose and temporary psychotic states and unpredictable behaviour 
 Hallucination and vomiting 
 Confusion leading to aggression and violence 
 Intense comedown that can cause users to feel suicidal 
 Increase in mental health issues, including psychosis, paranoia, anxiety, ‘psychiatric complications’ 
 Depression 
 Physical and psychological dependency  
 Temporary psychotic states and unpredictable behaviour 
 Drug-related overdose and death. 
 
2.13 CSEW data indicated that NPS use is strongly associated with the misuse of other illicit 
drugs (Home Office, 2015); 83% of adults who had taken another illicit drug in the previous 
year also reported that they had used NPS. People who had visited a pub or a nightclub or 
who had consumed alcohol in the previous month were significantly more likely to have used 
NPS in the previous year than those who had not.  
2.14 DrugScope7 undertook snapshot surveys of drug use in a number of towns and cities across 
the UK in 2013 and 2014. The 2014 survey reported a continuing rise in NPS – particularly 
synthetic cannabis – in most areas by opiate users, the street homeless, socially excluded 
teenagers and people in prison. The report quoted a Birmingham homeless charity, which 
stated that a large number of their opiate-using clients and street drinkers were smoking 
synthetic cannabis, leading to health emergencies: 
‘…They are using it because it’s cheap, it’s strong and because those who are out on licence will 
not go back to jail if they are caught taking them because they’re legal’  (Daly, 2014). 
2.15 It has been suggested that NPS use by groups, including prisoners, professionals, military 
personnel and younger users, may be driven by the wish to avoid detection or criminal 
sanction and some may use NPS as they are easier to access than preferred alternatives 
(Home Office, 2014).  
2.16 Few NPS users have accessed drug treatment services to date. NPS were recorded as the 
main drugs declared by less than 1% (144) of those accessing treatment in England in 2013–
14 (NAT, 2014). The stimulant NPS drug, mephedrone, appears to have had a greater 
prevalence in Wales than in England since 2009, particularly among those aged 15–29 (Smith 
and Emmerson, 2014), although it remains a very small proportion of overall presentations 
(1.4%). Synthetic cannabis referrals were not reported specifically in treatment data for 
Wales but may have been included in the 1% of referrals for ‘other’ drugs (Smith and 
Emerson, 2014). 
                                                                                                                                                                                     
7 DrugScope was a charitable organisation that was the national voice of the drug and alcohol treatment sector and was a 
prominent independent centre of expertise on drugs and drug misuse. It went into liquidation in March 2015.  
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2.17 National Drug Treatment Monitoring System (NDTMS) monitoring data revealed only a tiny 
number of prisoners receiving treatment for NPS, reflecting the similarly low rates in the 
community. For the period April to September 2014, across all prisons in England, only 121 
of the 56,000 adults treated for substance misuse issues were for NPS, with a further 119 
having NPS as a secondary drug (NTA, 2015); overall, this represents less than 1% of all 
those accessing treatment. The two most cited primary drugs that prisoners received 
treatment for were heroin (20,717) and cannabis (7,787); crack cocaine was the most cited 
secondary drug. 
2.18 Although the overall level of NPS use and the numbers coming forward to drug treatment 
services with NPS as a primary substance of concern are low, the European data available 
suggest that, as a group, NPS now constitute an important component of the overall drug 
problem, in terms of both prevalence and the health-related problems associated with drug 
use (Home Office, 2014). 
Misuse of medication in England and Wales 
2.19 Commonly misused prescription-only and over-the-counter (PO/OTC) medication includes 
painkillers, benzodiazepines8 and sedatives (NTA, 2011), and opioid substitution treatment 
medications such as methadone and buprenorphine. The risks associated with misuse of 
medication are similar to those of other illicit drugs, including adverse drug interactions and 
accidental overdose. 
2.20 The DrugScope 2014 street survey identified significant misuse of the prescription drugs 
pregabalin (which treats nerve pain and epilepsy) and gabapentin (which treats epilepsy), 
chiefly among Britain’s opiate-using and prison populations (Daly, 2014). Pregabalin enhances 
the desired effects of heroin while also reducing the undesirable effects of withdrawal 
symptoms (Wakeman and Seddon, 2013), making it more sought after for misuse than 
gabapentin, with a growing illicit market (Public Health England (PHE) and NHS England, 
2014). National guidance on the safer prescribing of these drugs, issued in December 2014, 
highlighted that both have a depressant effect on the central nervous system which is 
exacerbated when they are taken with other depressant drugs, including alcohol; this can 
lead to drowsiness, sedation, respiratory depression and, at the extreme, death. This means 
that extreme care needs to be taken when prescribing more than one depressant drug (PHE 
and NHS England, 2014). 
2.21 Questions on the misuse of prescription-only painkillers (but no other types of prescription 
drugs) were added to the CSEW in 2014–15. In this survey, 5.4% of adults reported misusing 
a prescription-only painkiller not prescribed to them in the previous year, and a quarter of 
adults who reported the misuse of prescription-only painkillers said that they had also taken 
another drug in the previous year (Home Office, 2015). A significant minority had taken 
them for reasons other than pain relief. 
2.22 The numbers presenting at community treatment services for PO/OTC medication are 
relatively low; 2% of new presentations to specialist drug services in 2009–10 (3,735) were 
for PO/OTC medication, with a further 14% (28,775) reporting it as a secondary drug (NTA, 
2011). More recent figures from Public Health England and NHS Wales indicated that the 
number of people presenting to specialist drug services remains low (NTA, 2014; Smith and 
Emmerson, 2014). A large proportion of those who present for drug treatment for heroin 
(NTA, 2011) and those on opiate substitution prescribing (Dale-Perera et al., 2014) report 
taking other medications concurrently, often procured from friends, street dealers or the 
 
8 Benzodiazepines are a tranquilizer used to treat anxiety, agitation and restlessness, epilepsy, mania, alcohol withdrawal and 
sleeping problems. 
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internet. However, many people who have issues with PO/OTC medication may not self-
refer, may not be identified or may be managed by their GP, with only the most complex 
cases presenting to specialist services. This makes it difficult to assess prevalence accurately 
(NTA, 2011; Reay, 2009). 
Addressing substance misuse: policy and treatment 
responses 
2.23 The reduction in drug-induced deaths, infectious diseases, other health consequences and 
offending are key policy issues. Drug strategies for England and Wales focus on supply 
reduction (by HM Revenue and Customs, police and courts), prevention (including 
communication programmes, such as Talk to Frank in England and DAN 24/7 in Wales plus 
focused support for vulnerable groups) and treatment through local multi-agency 
partnerships (EMCDDA, 2014).  
Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS)  
WEDINOS, started in 2009, is a local initiative in Wales testing samples of unknown/unidentified 
drugs provided by patients. The drugs were profiled and a process of mapping trends and harms was 
initiated. Since 2013, Public Health Wales and the Welsh Government have funded WEDINOS as a 
robust mechanism for the collection and testing of unknown/unidentified or new psychoactive 
substances and the production and dissemination of pragmatic harm reduction advice. Samples may 
be submitted by anyone in Wales, and participating organisations include hostels, nightclubs, mental 
health community teams, the Ambulance Service and the Police.  
 
2.24 Recent UK drug treatment strategies emphasise the importance of reintegration to 
sustaining recovery from substance misuse, including coordinated working between physical 
and mental health, housing, employment, criminal justice and drug treatment services to 
address the breadth of a user’s needs, including, but not exclusively, the physical symptoms 
of drug misuse (UK Focal Point, 2014). 
2.25 Since April 2011, the Department of Health has had responsibility for funding both clinical 
and non-clinical drug and alcohol treatment in all prisons and in the community in England. In 
Wales, health services are the responsibility of the Welsh Government, with responsibility 
for commissioning devolved to local health boards. 
2.26 2013 saw major changes to substance misuse treatment, with: 
 The functions of the NTA9 transferred to Public Health England 
 The absorption of a ‘ring fenced’ drug treatment budget into the wider public health 
funding pot 
 Increased discretion for new local decision makers and bodies, in line with the key Patel 
Report (2010) recommendation that integrated and needs-led treatment services are best 
commissioned at a local level. 
2.27 All communities in England and Wales have support services for those with a drug problem. 
Drug treatment incorporates a range of services, including advice and information, relapse 
                                                                                                                                                                                     
9 The NTA was created as a special health authority in 2001 to improve the availability, capacity and effectiveness of drug 
treatment in England. 
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prevention, aftercare programmes, needle exchange, blood-borne virus testing, opiate 
substitute prescribing, one-to-one and group-based psychosocial interventions, inpatient 
treatment, day programmes and residential rehabilitation. Most drug treatment is voluntary 
and referral can be by self or by other professionals such as probation officers, social 
workers or GPs. Some treatment can be mandated from police custody or by a court when 
offending is linked to drug misuse. Substitute prescribing for opiate dependence is provided 
for stabilisation, planned reduction, maintenance and relapse prevention but should always 
occur within a wider treatment package (UK Focal Point, 2014) of psychosocial 
interventions. As noted above, opiate users are over-represented in drug treatment. 
Drugs and crime 
2.28 Drug misuse and crime are strongly linked but the relationship is complex. Levels of drug use 
are high among offenders, with the highest levels of use reported among the most prolific 
offenders (Morgan, 2014). Some people are criminalised directly through their drug use. The 
police recorded 186,657 drug offences in the year ending September 2014, a decrease of 7% 
compared with the previous year, but 30% higher than in 2003–04. Some of these increases 
are linked with national targets, including penalty notices for disorder for possession of 
cannabis (Office for National Statistics (ONS), 2015). Cannabis possession has accounted for 
around two-thirds of all recorded drug offences every year since 2005–06 (ONS, 2015). 
2.29 Opiate and crack users are more likely to commit crime such as shoplifting and burglary to 
secure funds for drug use (Morgan, 2014; Bennett et al., 2008). Although a small minority of 
opiate and crack users commit a large number of offences, many of those who offend at high 
rates began their criminal careers before opiate/crack initiation (Morgan, 2014) and many 
opiate and crack users commit little or no crime. For some opiate and crack users, their 
drug use was a catalyst for offending but for others it accelerated and extended their 
criminal career (Morgan, 2014).  
2.30 The limited data available from the Probation Service suggest that the numbers being 
identified as having a drug misuse-related need are reducing. Between 2008–09 and 2011–12, 
the number of full offender assessment system (OASys) assessments completed for the start 
of a community sentence, suspended sentence or period on licence supervised by the 
Probation Service for which an offending-related need linked to drug misuse was identified 
fell by 55%, from 55,165 to 24,881. Of the 76,500 offenders assessed for and starting a 
community order between October 2009 and December 2010 as part of the Offender 
Management Community Cohort Study (OMCCS), 32% were identified as having an 
offending-related need linked to their misuse of drugs (including prescribed medication) 
(Wood et al., 2013).  
Treatment for those in the criminal justice system 
Community-based services 
Drug interventions programme (DIP) 
The DIP operated in most local areas in England and Wales, from 2003 to March 2013, to tackle 
Class A drug-misusing offenders. The service included actively offering treatment to those in police 
and court custody and ‘through-the-gate’ support to prisoners. In April 2013, Home Office funding 
for DIP was devolved to Police and Crime Commissioners (PCCs), and it is no longer a nationally 
regulated programme. 
Funding continued in 2014–15 but from 2015–16 it is unclear what will be funded and commissioned, 
and there is likely to be considerable variation between police and local authority areas (UK Focal 
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Point, 2014). Our police and court inspections in 2014 and 2015 indicated that police, court and 
through-the-gate prison services exist in different forms, with a significant variation in provision 
between commissioning areas. It is too early to comment on whether this has had an impact on the 
quality of provision.  
Drug testing on arrest 
Drug testing on arrest was introduced as part of DIP in 2003, to help to tackle drug-related 
offending, whereby police could request a drug test for heroin or crack for all those arrested. Not all 
forces drug test on arrest and some forces just test those arrested for an offence known to be linked 
to drug use – for example, acquisitive crimes. Those testing positive are required by law to undergo 
an assessment of their drug misuse, possibly leading to treatment. The positive rate between 2004–
05 and 2009–10 peaked at 47% in 2004–05 and fell to a low of 29% in 2009–10, the latest dates for 
which figures are available (Malik, 2010).   
Prison-based services  
Counselling, assessment, referral, advice and throughcare (CARAT) 
 
Psychosocial drug services were introduced into prisons in 1999 as the ‘CARAT’ service. This 
created increased consistency in psychosocial provision and included a welcome focus on 
resettlement activity following release from prison. Initially, the service was primarily staffed by 
prison officers. Since the transfer of commissioning to NHS England in 2013, these services have 
been provided primarily by specialist civilian drug treatment providers.  
 
The integrated drug treatment system (IDTS) 
Before 2006, there had been a large variation in the clinical treatment of prisoners who were 
withdrawing from opiates and alcohol. Around this time, a number of prisoners and ex-prisoners 
successfully sued the Prison Service for subjecting them to enforced unassisted opiate withdrawal. 
 
IDTS was phased in from 2006 in England to: 
 
 increase the volume and quality of drug and alcohol treatment available to prisoners, with a 
 particular focus on early days in custody, including the consistent and timely stabilisation of 
 opiate, alcohol and hypnotic withdrawals   
 improve integration between psychosocial and clinical services 
 reinforce the continuity of care between prisons and those released into the community.  
 
A key driver for the implementation of IDTS in English prisons was to reduce the number of 
incidences of relapse and death by drug overdose on release from prison. 
 
Prison inspections have found that IDTS has reduced the demand for heroin in prison and improved 
outcomes for prisoners, although formal evaluation findings for the programme are not yet available.  
 
Substance misuse services in prison are generally no longer referred to as ‘CARAT’ and ‘IDTS’. They 
are sometimes referred to as substance misuse services but many prisons have chosen names that 
promote recovery, for example the Drug and Alcohol Recovery Team (DART) at HMP Littlehey or 
the Substance Treatment and Recovery (STAR) team at HMP Manchester. 
 
Addressing NPS misuse 
2.31 In 2012, the UK Government recognised that the use and availability of NPS were changing 
the UK drugs market, and published an action plan to tackle them (HM Government, 2012), 
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to reduce demand and supply and ensure that effective treatment and support were 
available. The Government has continued to develop new strategies to address NPS, 
including new legislation proposed in the Queen’s speech in May 2015 to ban the new 
generation of psychoactive drugs. Organisations including HMI Prisons and the Advisory 
Council on the Misuse of Drugs (ACMD) have broadly supported this legislation but have 
recommended some revisions (ACMD, 2015; House of Commons Home Affairs Committee, 
2015). Particular concern, for example, has been raised about the breadth of the term 
‘psychoactive substances’ used in the Bill. It includes any substance that affects the 
physiological and/or psychological functioning of the brain and does not discriminate between 
benign/potentially beneficial and potentially harmful effects.  
2.32 Community commissioners that we interviewed for this thematic inspection report said that, 
although there was an increasing issue with NPS in their locality, they lacked any clear data 
on prevalence. They also reported low levels of engagement with services by primary NPS 
users. Although they were able to support people with NPS issues, most did not offer a 
dedicated NPS service. NPS were a key strategic priority for some commissioners and some 
were trying to increase understanding of the issues and service needs of NPS users. For 
example, Brighton and Hove commissioners have identified NPS as an increasing issue and 
formed a working group looking at need; they have improved the accessibility of treatment 
by running a clinic specifically for NPS. In 2014, Public Health England issued guidance on 
commissioning NPS services in the community which included brief references to prisons 
(PHE, 2014a).  
Addressing the misuse of medication 
2.33 The NTA review on addiction to medicine (NTA, 2011) noted a large variation in provision, 
the need for greater national clarity on the best approach to use, and the importance of 
understanding the local problem. The review also recommended a range of strategies to 
address dependency on PO/OTC medicine, including: 
 
 Strict guidelines to prevent diversion 
 Appropriate evidence-based prescribing and reviews 
 Effective medicine management committees 
 Auditing of prescribing  
 Providing warnings about the risks of dependence  
 Training staff. 
2.34 Commissioners interviewed for this thematic inspection reported a hidden population who 
misused PO/OTC medication and who were not engaging with their services. Some 
reported an increase in medicine misuse in the community and in those released from 
prison; this was reportedly being addressed by educating prescribers.
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Section 3. Substance misuse in prisons 
3.1 Patterns of substance misuse in prisons have never directly reflected those found in the 
community. In prisons, there has traditionally been a preference for using depressants such 
as heroin and cannabis, which will help prisoners to ‘kill time’, over stimulants such as 
cocaine, crack cocaine and ecstasy, which many associate with a ‘club’ or party scene in the 
community. This thematic study set out to explore recent changing patterns of substance 
misuse in prisons, such as the move towards medications and new psychoactive substances 
(NPS), and away from Class A drugs and cannabis. 
3.2 While drugs are available in prison, there is generally less choice, a lower purity and less 
availability, but at a higher price than in the community. Additionally, an emphasis in prison 
on supply reduction, including drug testing and searches, makes detection more likely than in 
the community, and the consequences for individuals of using small amounts of drugs are 
potentially greater in prison than in the community. Sanctions can include loss of privileges, 
return from open to closed conditions and time added on to sentence. Nevertheless, 
substantial numbers of prisoners misuse drugs and medications, and factors such as the 
availability of drugs and potential for sanctions if caught using them drive some of the 
changes in drug use patterns in prison compared with the community. 
Substance misuse before arrival in prison 
3.3 As described earlier, offenders have higher rates of substance misuse than the population as 
a whole, so a high number of entrants to prison will have a history of drug-taking and some 
will report problems related to their use, including dependence. However, much of the 
available research on prevalence is dated, meaning that recent changes are not reflected 
owing to the fast pace with which drug use in prisons is evolving. 
3.4 The 2013 Surveying Prisoner Crime Reduction (SPCR) longitudinal study (Light et al., 2013) 
provides some useful information on prisoners’ drug use but predates the changes in 
community drug use described in the previous chapter, the advent of NPS and the full rollout 
of the integrated drug treatment system. The SPCR study followed 3,849 adult prisoners 
from 2005–06, sentenced to between one month and four years in prison in England and 
Wales, looking at reported drug history and reoffending. Key findings included: 
 Rates of illegal drug use were higher among prisoners than offenders on community 
orders and the general population.  
 81% reported having taken an illicit drug at some point in the past and 64% reported 
having taken drugs in the four weeks before their imprisonment.  
 Prevalence rates for lifetime illicit drug use were highest for cannabis (71%), followed by 
powder cocaine (45%), crack cocaine (43%), ecstasy (42%), amphetamines (41%) and 
heroin (40%).  
 27% of males and 36% of females reported using unprescribed tranquillisers, while 20% of 
males and 27% of females reported using unprescribed methadone. 
 Female prisoners reported more Class A drug use in the four weeks before custody than 
male prisoners, and were also more likely to report that their offending was to support 
someone else’s (as well as their own) drug use. 
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3.5 In our survey for this thematic inspection, 52% of respondents said that they had used illicit 
drugs or medication in the two months before going into prison. This is much higher than 
the general community prevalence reported in the CSEW, but lower than that suggested by 
the older SPCR study (Light et al., 2013), which may reflect the overall trend of reducing 
illicit drug use highlighted by the CSEW. Reported prior drug use in the community was 
much higher among younger prisoners than those aged 50 and over (see Figure 1). 
Figure 1: Reported drug use in the two months before going into prison, by age 
(N=1,37610) (HMI Prisons thematic survey) 
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3.6 Cannabis was the most commonly reported drug used before going into prison (38%), 
followed by cocaine (29%). Our survey findings showed that the level of NPS use before 
going into prison was low relative to other substances, at 6% for Spice/Black Mamba and 5% 
for legal highs (Figure 2).11 When interviewed, prisoners who said that they had used NPS in 
the community before going into prison had generally used it with other drugs or with illicit 
medication. The primary drugs that they said they had taken along with NPS were heroin and 
cannabis. The reported prior use of NPS and legal highs was lowest in open prisons, which 
may reflect the fact that NPS may have emerged in the community only after some 
respondents had entered prison. 
3.7 One in 10 prisoners said that they had used either opiate substitute medication (9%) or 
other medication not prescribed to them (10%), and this had only been used in combination 
with other primary drugs, mainly heroin. 
 
 
 
 
10 The N number refers to the number of valid responses.  
11 The terms ‘Spice/Black Mamba’ and ‘legal highs’ were used in the prisoner survey as they were more widely recognised 
by prisoners than ‘synthetic cannabis’ and ‘NPS’. 
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Figure 2: Reported drug use in the two months before going to prison by type of drug* 
(N=1,384) (HMI Prisons thematic survey) 
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* The total of all types of drug is greater than 100% as prisoners could report having taken more than one 
drug. 
Substance misuse on arrival in prison 
3.8 A high proportion of prisoners enter prisons with drug and alcohol problems. National 
treatment data showed that between April and September 2014, a quarter (25%) of all new 
entrants into prisons in England began treatment for substance misuse (including alcohol) 
within three weeks of their arrival. 
3.9 In published HMI Prisons inspection surveys between April 2014 and August 2015, 28% of 
respondents (N=10,702) reported having a problem with drugs on arrival in prison. Women 
are under-represented in drug treatment services and report less drug use in the community 
than men, but levels of drug dependence among female prisoners have been found 
consistently to be higher than among male prisoners (Fazel et al., 2006; Singleton et al., 
2003). This is reflected in the HMI Prisons inspection survey findings for the afore-mentioned 
period, which showed that a significantly higher proportion of female than male prisoners 
had a problem with drugs on arrival in prison (41% versus 27%). Those with mental health 
problems were also significantly more likely to say they had a problem with drugs when they 
went into prison. 
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Substance misuse in prisons  
3.10 Although there are no concrete data, it is clear from inspections of prisons, including 
interviews with staff and prisoners, that the use of Class A drugs and cannabis, as evidenced 
by mandatory drug testing (MDT) finds and prisoner and staff reports, has reduced but not 
ceased in the past 4–5 years. 
3.11 In our additional survey in eight prisons (N=1,376), more than a quarter of respondents 
(26%) said that they had taken either illicit drugs or medication in their current prison. There 
was significant variation in the reported level of use by age. The highest level of use of any 
illicit substance was reported by those aged 30–39 (31%) and the lowest was in those aged 
50 and over (14%). 
3.12 A lower proportion of women than men said that they had used illicit substances in the 
prison (19% versus 26%). There was only one women’s establishment in our sample of eight 
but this finding is consistent with findings from our wider inspections. Generally, finds, MDT 
results and reports from staff and prisoners in women’s prisons indicate that illicit drug 
misuse, including NPS, is less common among women than men. Medication, including 
diverted medication, is typically more sought after by women; however, synthetic cannabis 
was reported to us as an emerging issue in an inspection of a women’s prison in 2015 for the 
first time. 
The diversion of medication continued to be an issue but appropriate steps were being taken to monitor and 
address it, although some aspects of supervision around medication queues needed to improve. Intelligence 
reports and finds had indicated that in the months prior to the inspection new psychoactive substances… had 
emerged as a further concern. HMP New Hall 2015  
3.13 Similar levels and patterns of use were reported for illicit drugs only compared with illicit 
medication only, as shown in Figure 3 (overall, 18% in each case). 
 
 
Figure 3: Illicit substance misuse in current prison, by age (N=1,376) (HMI Prisons 
thematic survey) 
  
 
27%
20% 19%
31%
22%
16%
14%
7%
9%
26% 23%
26%
17%
18%18%
0%
5%
10%
15%
20%
25%
30%
35%
Illicit substances Illicit drugs only Illicit medication only
Pr
op
or
tio
n
Age under 30 Age 30-39 Age 40-49 Age 50 and over All prisoners
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 3. Section 3. Substance misuse in prisons 
 Changing patterns of substance misuse in adult prisons and service responses 31 
3.14 Patterns of drug use in prisons change and, in the same way that use of synthetic cannabis 
overshadowed the misuse of diverted medication during and since the fieldwork for this 
study in 2014, it is likely that the prevalent drugs of misuse may change again as disruption to 
the supply of synthetic cannabis improves. This may vary between prisons and within a 
prison over time, based on multiple factors, including prevalent drug trends in the 
surrounding community and the effectiveness of supply reduction strategies. In prisons 
where there are fewer drugs coming in, medication diverted within the prison or the seeking 
of clinically inappropriate prescribing will be in greater demand. Anecdotal evidence in some 
prisons suggests spikes in illicitly brewed alcohol in the immediate aftermath of large finds 
which reduced the availability of synthetic cannabis. 
3.15 We have not looked specifically at tobacco in this thematic inspection report but the future 
implementation of the smoking ban in prison is likely to be a driver to change patterns of 
drug misuse in prison again. Most prisoners smoke and this has health consequences, not 
only for those who actually smoke, but also for other prisoners and staff who live and work 
in the same environment. In establishments where smoking is currently banned, such as 
those holding young people, we consistently observe that this creates a market for illicit 
tobacco. We inspected HMP Isle of Man in March 2011 and found that a smoking ban had led 
to large-scale trading in illicit tobacco, prisoners being bullied for nicotine replacement 
therapy, and dangerous practices to light home-made cigarettes. 
The total prison ban on smoking tobacco had resulted in a large number of negative outcomes. Staff had 
stepped up efforts to detect illicit tobacco and its substitutes, evidenced by the 63 smoking material-related 
finds in the six months from September 2010 to February 2011, compared with nine drug and six hooch 
finds. The widespread demand for scarce tobacco or its alternatives had also resulted in some prisoners being 
bullied for nicotine patches on arrival at the prison or when they obtained their patches from the health care 
department. … Prisoners showed us how they rendered and extracted nicotine from the patches for addition 
to ‘alternative’ smoking materials, which included dried fruit peel and tea. Some fruit was subsequently 
banned but prisoners also used lint from tumble driers and even pubic hair. The full extent of the risks to 
health posed by smoking such substances are largely unknown, although nurses told us that many prisoners 
presented with sore throats. HMP Isle of Man 2011 
3.16 The potential health benefits of the smoking ban for staff and prisoners are clear and, 
although it may also lead to a reduction in the smoking of NPS, and synthetic cannabis in 
particular, it may also lead to more use of other NPS. The ban will need to be managed 
carefully, to ensure that it does not lead to an increased illicit market for other harmful 
substances, with the associated adverse effects on safety and security. 
Specific substances used in prison 
3.17 Drug availability and use varies across different prisons and between regions. Previous 
research has shown that prisoners have a high prevalence of polydrug use and dual diagnosis 
(both substance misuse and mental health problems) (Patel, 2010). This was confirmed by 
our fieldwork for this thematic inspection. 
3.18 Different drugs are typically available in the community than in prisons; therefore, when 
offenders enter prison, their substance misuse may change. Prisoners we interviewed 
reported that their drug use altered in prison according to the substances that were 
available. This could include multiple drugs at the same time or different drugs on different 
days, both of which practices carry a significant risk of harm, including drug interactions and 
accidental overdose. 
3.19 Figure 4 shows the illicit drugs that prisoners reported using in their current prison. 
Cannabis (13%) and synthetic cannabis (Spice/Black Mamba; 10%) were more frequently 
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reported as having been used than other drugs. Reported use of Spice or Black Mamba was 
also higher in prisons than in the community, with only 6% of those surveyed saying that they 
had used one of these drugs in the two months before going into custody. Our inspection 
findings, including MDT results, also demonstrate that cannabis remains a popular drug in 
prisons, as it is in the community, and this may also be a significant additional factor in the 
popularity of synthetic cannabis, as it is similar in effect, with lower risks of detection.   
 
Figure 4: Reported drug use in current prison by type of drug* (N=1,384) (HMI Prisons 
thematic survey) 
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* The total of all types of drug is greater than 100% as prisoners could report having taken more than one 
drug. 
3.20 Figure 5 shows how use in the two months before going into prison differed from use in 
their current prison. 
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Figure 5: Reported drug use in the two months before going into custody and in current 
prison, by drug (N=1,384) 
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3.21 Women and older prisoners were less likely than men and younger prisoners to say that 
they had used synthetic cannabis, reflecting patterns of use in the community. For example, 
just 3% of prisoners in the women’s prison said that they had taken Spice specifically, 
compared with 11% of prisoners in the seven male establishments (N=1,384). In addition, 
only 2% of those aged 50 and over reported taking Spice or Black Mamba, compared with 
13% of under-30s (N=1,376). 
Diverted medicines 
3.22 The diversion of medications is a serious problem in prisons. The most commonly diverted 
medications in prison are those that have a depressant effect on the nervous system, 
reflecting a desire to blunt emotions (Bullock, 2003). Buprenorphine has been a drug of 
misuse in prison for several years – even in establishments that do not prescribe it (Ministry 
of Justice (MOJ), 2007) – and prisoners have reported snorting it rather than taking it under 
the tongue (as it should be taken), to achieve an increased effect (Tompkins et al., 2009). 
Some prisoners we spoke to confirmed that they snorted buprenorphine; one prisoner 
described it as being ‘for a head buzz’. Other medications, including benzodiazepines, anti-
depressants and painkillers, have been reported by staff and prisoners as being popular 
because of their low cost, availability, perceived undetectability and guaranteed effect 
(Penfold et al., 2005; Plugge et al., 2009). 
3.23 We first reported on the widespread misuse of diverted medication (see Annex) in high 
security prisons and vulnerable prisoner populations inspected in 2010–2011 (HM Chief 
Inspector of Prisons for England and Wales, 2011). By 2012–13, this had spread to 
mainstream prison populations (HM Chief Inspector of Prisons for England and Wales, 
2013).  
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… There has been a steady increase in the reported abuse of prescribed medication, where medication is 
‘diverted’ by someone for whom it was not prescribed. Prisoners might sell their own medication or have it 
taken from them through theft or bullying. The risks of diverted medication include bullying, drug debts, 
unexpected drug interactions and overdose. Medication commonly diverted includes certain painkillers, 
sedatives and psychiatric medication. Many of these medications cannot be detected by mandatory drug 
testing (MDT), or there are no legal powers to do so, and consequently, as highlighted in our 2010–11 
report, MDT is no longer an accurate measure of drug use in British prisons. We also found that suspicion 
drug testing – which could detect some diverted medication – was not adequately completed at a third of the 
prisons we visited. HM Chief Inspector of Prisons Annual Report 2012–13 
3.24 Varied guidance on prescribing has been published as patterns of misuse have emerged (PHE 
and NHS England, 2014; Royal College of General Practitioners Secure Environments Group, 
2011). For example, Buscopan (hyoscine butylbromide), a medication which is used for 
stomach cramps, particularly during opiate reduction in prison settings, emerged as a drug 
that is being misused by prisoners as it can give some euphoric effects, and prescribing 
guidance was issued in 2015. In June 2014, tramadol (a painkiller for moderate-to-severe 
pain) was reclassified as a controlled drug, prompting a reduction in prescribing and more 
tightly controlled administration in most establishments. We have observed a large reduction 
in the number of prisoners being prescribed tramadol since then, but the prescribing of 
other pain killers has increased, creating an alternate market. 
3.25 In our survey of eight establishments for this thematic inspection, prisoners were asked 
which illicit medications they had taken in their current prison. The findings are shown in 
Figure 6. The most commonly used illicit medications were painkillers and medication to 
assist sleep. In addition, 6% of respondents who said that they had used illicit medications 
while in prison reported that they had come to rely on medication while in prison. 
 
Figure 6: Illicit medication use in current prison, by type of medication (excluding over-
the-counter medication) (N=1,384)*12 
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* The total for all types of medication is greater than the figure for at least one illicit medication as prisoners 
could have taken more than one type of medication. 
                                                                                                                                                                                     
12 The terms ‘sleepers’ and ‘subutex’ were used in the questionnaire as they were viewed as being more recognised by 
prisoners than the formal names.  
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NPS use 
3.26 Synthetic cannabis (more specifically, Spice) was first identified to HMI Prisons as a serious 
problem in December 2011 at the inspection of HMP Standford Hill, but was not identified 
as a widespread issue until 2013 onwards. In the 2013–14 annual report (HM Chief Inspector 
of Prisons for England and Wales, 2014), synthetic cannabis was identified as a concern by 
HMI Prisons in a third (37%) of male prisons inspected, and this increased to 64% in 2014–15 
(HM Chief Inspector of Prisons for England and Wales, 2015). 
 
In this reporting year, diverted medication (that taken by someone other than for whom it was prescribed) 
was reported as an issue in 19 (50%) adult male prisons fully inspected. NPS, specifically ‘Spice’ and ‘Black 
Mamba’, were cited as causes for concern at 14 (37%) of the adult male establishments inspected, 
particularly local and category D jails. Although many prisons had taken steps to promote awareness of this 
problem, we highlighted the need for some to give prisoners and staff accurate and up-to-date information on 
the acute health dangers associated with NPS. HM Chief Inspector of Prisons for England and 
Wales Annual Report 2013–14  
 
Last year, we warned that the development of new and largely non-detectable psychoactive substances (NPS) 
– such as ‘Spice’ and ‘Black Mamba’ – was a dangerous new trend in prisons, and our findings this year 
confirmed that their use had grown, leading to problems such as bullying, debt and medical emergencies 
requiring hospitalisation. National measures to combat this were still in development throughout most of 
2014-15: MOJ policy guidance to prison governors was distributed in February 2015, and changes to 
legislation had not yet come into effect. HM Chief Inspector of Prisons for England and Wales 
Annual Report 2014–15  
 
The extent of the problem identified on inspection varied across prisons and regions. 
Inspections have found that synthetic cannabis has become the most prominent substance 
misuse issue in the previous 18 months in most prisons, with many staff and prisoners 
reporting high levels of use and associated problems, but the extent of use is not quantifiable. 
Synthetic cannabis under various names was identified as a problem in every inspection 
report published between January and August 2015. However, synthetic cannabis was rarely 
the only issue; it was generally part of wider patterns of misuse that also included diverted 
medication and illicit drugs, including cannabis. In some prisons we inspected, we observed 
that their focus on synthetic cannabis alone was leading to an increase in the misuse of other 
drugs that was going largely unchallenged. Prisons need to have a whole-prison approach to 
the misuse of all drugs, to prevent alternatives emerging and becoming problematic. 
3.27 Staff and prisoners we spoke to as part of this thematic inspection told us that synthetic 
cannabis is popular in prison because it is undetectable and cheap, and has a guaranteed 
effect. It is attractive to supply because there are no penalties for its possession in the 
community. It is cheap to buy or manufacture and, although, in prison, prices are lower than 
for other substances, the difference between the community and prison price is much 
greater than for substances that are illegal in both environments and so profits are greater. 
Low costs, low risks of detection or penalties, and large profits make it attractive to supply 
in large quantities. Research undertaken for this thematic study confirmed Spice to be a 
significant issue in prisons currently, and prisoners suggested that it is a new drug of choice 
in prisons in England. 
3.28 Many prisoners we interviewed referred to having witnessed the ill-effects of synthetic 
cannabis. For example, one prisoner said that he had seen prison officers and his cell mate 
attacked because someone was ‘out of control’ on Mamba. Prisoners who said they had tried 
Spice said that it made them variously paranoid, hypersensitive, ‘feel guilty about things’, 
depressed and easily wound up. Staff and prisoners told us that prisoners could not recall 
what they had done while under the influence of synthetic cannabis once the effects had 
worn off. Some prisoners we spoke to had been warned about the dangers of using synthetic 
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cannabis, or showed some awareness of the varied and sometimes unknown substances it 
could contain, and the associated risks. Staff we interviewed admitted that they needed to 
know more about synthetic cannabis and NPS and their effects, in order to detect use and to 
deal better with the associated problems.  
3.29 As noted above, NPS, including synthetic cannabis, cover a range of substances that may 
contain different active ingredients. Therefore, prisoners do not necessarily know what 
exactly they are using or the effect it will have on them. 
3.30 A large proportion of adult male establishments inspected since 2013 reported incidents 
when emergency medical assistance had been required for prisoners as a result of synthetic 
cannabis use. 
3.31 Recent inspections have found that the number of medical emergencies has decreased in 
establishments with long histories of synthetic cannabis use but remains high in 
establishments where the use of synthetic cannabis is a more recent phenomenon. This may 
reflect reduced use because of both increased awareness by prisoners of the potential risks 
involved, and the effectiveness of measures to limit supply. However, it may instead mask 
continued use as prisoners become more adept at looking after each other when overdosing, 
to avoid receiving sanctions for NPS use. This not only increases the risk of serious health 
consequences for prisoners, but also reduces the likelihood of prison staff being aware of 
such incidents. Most prisons do not keep accurate records of suspected medical emergencies 
or bizarre behaviour attributed to illicit drugs (including synthetic cannabis), which means 
that opportunities for individual establishments and the Prison Service to monitor and learn 
from these are limited. 
3.32 In addition, new products are being tested by prisoners before being circulated within 
prisons. Some prisoners may choose to be the tester in return for free drugs. We have been 
given credible accounts of prisoners, referred to as ‘spice pigs’, who are forced or tricked 
into testing new strands of Spice before they are used more widely in the establishment, to 
find out what quantities are safe, and what effects can be marketed. We were told that spice 
pigs tended to be more vulnerable prisoners or those who were in debt. Interviewees also 
told us that this could be a source of entertainment for other prisoners or a means to 
encourage an addiction in the hope that they became buyers in the future. 
Developing substance misuse problems while in prison  
3.33 In published inspection reports between April 2014 and August 2015 (N=10,702), 8% of 
male and 4% of female prisoners who took part in our confidential survey said that they had 
developed a problem with illegal drugs since they had been in the prison. What prisoners 
define as a problem is unclear; it could be a dependency, bullying or debt related to either 
their own or others’ substance misuse. We also have no way of ascertaining what 
proportion of these initiated drug use in prison for the first time in their lives or who had 
previous drug issues. Among all prisoners, the proportion who had developed a problem 
with illegal drugs varied from 3% in open prisons to 10% in category C training prisons. Only 
1% of those aged 50 and over said that they had developed a problem with drugs. 
3.34 Since 2012, we have included a question on diverted medication in our survey in all of the 
prisons we inspect. The proportion of prisoners surveyed reporting that they had developed 
a problem with diverted medication has remained reasonably constant, at 7–8%, over the 
previous three years. In our inspection surveys published between April 2014 and August 
2015 (N=10,702), 7% of male and 7% of female prisoners said that they had developed a 
problem with diverted medication. The lowest rate was 2%, in open male prisons, compared 
with a high of 8% in male local, and in category B training prisons. Consistent with other 
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findings, the proportion was lower among older prisoners, with only 4% of those aged 50 
and over reporting that they had developed a problem. 
3.35 Figure 7 shows the proportion of prisoners who had developed a problem with illegal drugs 
or illicit medication (or both), alongside the proportion who said that they had had a 
problem before entering prison, in reports published between April 2014 and August 2015. 
It shows clearly that women were more likely to report a problem with illicit drugs on entry 
but less likely to report developing a problem while in prison. Similar proportions of men 
and women reported developing a problem with diverted medication. There are fewer 
women’s prisons but, in the previous two years, we have reported much more positively on 
the flexibility of prescribing and the support provided in women’s establishments, which may 
have had an impact on drug misuse in these prisons. 
 
Figure 7: Problems with illicit substances, by gender (N=10,702) 
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Reported reasons for substance misuse in prisons 
3.36 As noted above, a high proportion of prisoners report using drugs before imprisonment and 
may then be more predisposed to use drugs in prison. In our interviews, prisoners reported 
various reasons for using drugs in prison, as set out below. 
Boredom and stress 
3.37 Relieving boredom appears to be an important factor in the use of drugs in prison. 
Depressants result in decreased awareness of surroundings, decreased alertness and blunted 
emotions, which prisoners reported to be desirable within a prison environment (Bullock, 
2003). For example, in the interviews, prisoners described using drugs in prison as a means 
‘to get out of the cell’ and that using drugs helped the sentence to pass more quickly:  
 
‘People take it [drugs] to pass the time. It’s hard being in one room for 24 hours’.  
‘Here, everyone is always looking for something to take; no work going on, so take something 
and get a bit of a lift’. 
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‘Being “out of it” makes the time pass quicker; at weekends it is worse than weekdays. I take 
drugs first thing in the morning and then the day passes without dragging’. 
3.38 Within the thematic survey, prisoners who said that they had a job in the prison were 
significantly less likely than those who had no job to say that they had taken drugs in their 
prison (17% compared with 20%), and those who reported spending more than 10 hours out 
of their cells on a weekday were also significantly less likely than those who did not to 
report illicit substance misuse (13% compared with 19%) (N=1,161). 
3.39 The HMI Prisons 2014–2015 annual report (HM Chief Inspector of Prisons for England and 
Wales, 2015) highlighted that we had judged outcomes for purposeful activity to be good or 
very good in only 25% of the adult male prisons we inspected in that period,13 the worst 
outcome since we started measuring them in 2005–06. We also reported that one in five 
prisoners said that they spent less than two hours a day out of their cells during the week 
and only one in seven spent 10 hours or more out of their cell each day. A lack of sufficient 
purposeful activity is likely to make the misuse of substances more attractive.   
Self-medication for physical and/or mental health issues 
3.40 There can be differences between what is prescribed in the community and what individual 
prisons prescribe, and this can result in changes in medication or dose. In our interviews for 
this thematic inspection, some prisoners said that differences in prison prescribing had 
prompted them to seek illicit substances or medications to compensate for or to mask any 
ill-effects from the change: 
‘They [health services staff] don't give you the meds you were prescribed on the outside, so 
people look to trade them illegally to fill the gap’. 
‘When I first came in, I was self-medicating; there was such a delay getting on to a script that I 
had to use in the meantime. The prison is very strict with prescriptions – I was offered 
methadone at first but did not want to take it as you can still use on top’.14 
3.41 Other prisoners said that they took drugs to help them sleep, which, as the prisoner below 
described, could be a problem during planned reduction from either medication or illicit 
drugs: 
 
‘I started taking subbies [subutex] when doing diazepam detox. Helped me sleep and deal with 
diazepam withdrawals’. 
Physical or psychological dependence 
3.42 During interviews for this thematic inspection, some prisoners told us that they continued to 
use illicit drugs in prison as they were addicted to them, and their use within prison was a 
continuation of what they would have been using in the community. Continued use was also 
a habit for some prisoners we spoke to: 
‘[Cannabis] is “normality” – been using it most of life anyway’.  
 
13 The Chief Inspector of Prisons’ Annual Report for 2014–15 covers all reports published by HMI Prisons between April 
2014 and March 2015. 
14 ‘Use on top’ refers to being able to take and feel the effects of illicit drugs alongside prescribed opioid substitution 
treatment, something that is possible with methadone but not with higher doses of buprenorphine. 
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‘Comfortable using it [buprenorphine] – keeps me away from heroin. I would rather use subutex 
than heroin’.  
3.43 Additionally, imprisonment can bring many stresses, deprivations and triggers for drug 
misuse which may also create demand for depressants. Alcohol, which may be used as a prop 
or create dependence in the community, is also prohibited in prisons, and this might increase 
the demand for alternative illicit substances. 
Drug use and mental health problems 
3.44 The co-existence of mental health and substance misuse problems is widely recognised and 
was highlighted in the Patel Report (2010), the Bradley Report (2009) and our mental health 
thematic report (HMI Prisons, 2007). The Chief Medical Officer annual report 2014 
highlighted the importance of integrating wider mental health care with addiction care 
provision (Strang et al., 2014). 
3.45 In our general surveys of prisons, we ask prisoners if they have any emotional well-being or 
mental health problems. We compared the answers of those who answered ‘yes’ against 
those who answered ‘no’ to this in our adult prison inspections published in 2014–15. Figure 
8 presents these findings. 
 
Figure 8: Reported drug use, by emotional or mental health problem (N=10,173) 
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3.46 Prison provides an opportunity to achieve abstinence. In our prisoner interviews for this 
thematic inspection, some prisoners said that the relative lack of substances available in 
prison compared with the community meant that they were less tempted, and better able to 
stop taking drugs in the prison: 
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‘Cannabis is expensive and I cannot justify spending that much tobacco on drugs to myself’.  
‘I don’t really use drugs [heroin, crack] in the prison; I don’t have the money for it – especially 
not enough money for the quantity of drugs that I would want to take. I also prefer injecting 
drugs and would not do that in a prison. I also prefer stimulants, which are not really available in 
the prison – not really a prison thing’.  
3.47 Some prisoners also reported that sanctions and negative repercussions for them prevented 
them from using illicit drugs and medications while in prison: 
‘Never been tempted, as a lifer, and all it takes is me taking a drug once and I would be 
targeted for testing, which would delay my release date’.  
‘I don’t smoke weed because there is no point – I want to get out of jail. It makes me paranoid 
in case I fail an MDT, which would make me lose my enhanced status’.  
 
‘I have too much to lose; I’m a cleaner and work on the servery and would lose that if I was 
caught using drugs again’. 
Problems associated with substance misuse in prisons 
3.48 Illicit drug use in prison leads to most of the same negative outcomes for users as for those 
in the community, including overdose, dependence and debt; however, these problems may 
be more pronounced in prison. The adverse consequences arising from the availability of 
synthetic cannabis in prison applies to a lesser or greater degree to all drugs. The drugs 
available are generally of a lower purity and a higher price than those in the community, 
which often leads to polydrug use of varied medicines and drugs to get an effect; this 
increases the risk of physical harm and exacerbates debt problems.  
3.49 Many prisoners have very low incomes in prison (particularly if they are not receiving 
additional funds from family or friends outside) – often under £10 a week. Debts spiral 
quickly owing to the informal credit terms in many prisons, whereby prisoners may have to 
pay back double the amount borrowed. It is not just drug users who get into debt; debts 
may be passed on to friends or cellmates if they have not been paid in full before a prisoner 
is released. Debts may be enforced by placing pressure on family members and friends in the 
community, either by threatening them directly or threatening to harm the prisoner if the 
debt is not paid. We were told that large sums of money may pass through supply chains, 
with profits used to fund other criminal activity. Prisoners explained that they sometimes 
sold their own prescribed medication to pay their debts or to pay for other drugs. Others 
we interviewed said that prisoners had to sell or transport drugs to repay their debt, while 
others gambled to try to pay off debts (playing dominoes, for example), which increased the 
risk of their debts increasing.  
3.50 Illicit drug use in prison also contributes negatively to many aspects of prison life, including 
violence, indiscipline and bullying. Some instances of violence can be directly linked to drug 
use – for example, aggression as a side effect of use or violence/threats of violence to 
procure medication/drugs or related to drug debts. 
 
The availability of drugs, particularly new psychoactive substances (… such as ‘Spice’ and ‘Black Mamba’), 
were a significant factor in much of the violence and these had also been the cause of regular hospital 
admissions. HMP Altcourse 2014 
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Levels of violence were high and many incidents were serious… The presence of new psychoactive substances 
(NPS), the pressure to obtain them and associated debt were among the causes, along with gang affiliations 
and an increasing number of category B prisoners. HMP Dovegate 2015 
3.51 The HMI Prisons 2014–15 annual report highlighted increasing levels of violence in adult 
male prisons over the previous five years, including serious assaults by prisoners on other 
prisoners and by prisoners on staff (HM Chief Inspector of Prisons for England and Wales, 
2015). A number of potential contributory factors were identified, including the rapid 
increase in the availability of synthetic cannabis, and particularly its impact on debt and 
associated violence. The National Offender Management Service (NOMS) has also 
highlighted NPS and their links to prison violence as a significant issue and a key priority for 
2015–16 (NOMS, 2015a). Illicit drug use, alongside the associated debt and violence, can 
have a destabilising effect on prisons, as we found at HMP Guys Marsh (2014). 
 
Levels of violence in the prison were very high and many prisoners were frightened. Almost a quarter of 
prisoners told us that they did not feel safe at the time of the inspection. In the six months before the 
inspection, there had been 17 assaults on staff, 53 assaults on prisoners and 19 fights – three times the level 
at our previous inspection. The violence was driven by the supply of drugs, particularly synthetic cannabinoids 
such as ‘Spice’. Subutex, diverted prescribed medication and illicitly brewed alcohol were also problems. Sixty-
five per cent of prisoners told us that it was easy to get drugs in the prison and 50% alcohol. We were told 
that much of this trade was led by gangs and by organised crime operating outside the prison. Although the 
price of the drugs on the streets was low, it was very high in prison, so there were attempts to get large 
quantities in – even if there were significant interceptions, big profits could be made. Most of the drugs were 
legal outside the prison and there was no effective way to test for them, so the risks of supply were low. 
There had been a number of medical emergencies and hospital admissions associated with the consumption 
of Spice. The supply of drugs led to debt, and debts were enforced by violence or threats of violence to 
prisoners or their family and associates outside the prison. Gangs operated openly in the prison. HMP Guys 
Marsh 2014 
3.52 Some prisoners surveyed in inspections published between April 2014 and March 2015 
reported being victimised by other prisoners for reasons related to drugs (4%) or 
medication (5%). In addition, 9% of prisoners who completed the thematic survey said that 
they had been pressured to give away their medication. Prisoners we interviewed for this 
thematic inspection said that violence was sometimes related to heightened emotions when 
drugs were not available, and to some prisoners retaliating because they had not had the 
opportunity to buy an illicit substance or had not received a promised illicit substance. They 
also said that if they were involved in a fight over drugs, they would not admit this to 
officers. Staff interviewed for this thematic inspection acknowledged that violence related to 
drugs was a problem and was one of the reasons for developing improved strategies to 
prevent substance misuse. 
3.53 As noted above, a large proportion of adult male establishments inspected since 2013 
reported incidents where emergency medical assistance had been required for prisoners 
because of synthetic cannabis use. Emergency ambulances had been called to attend to 
prisoners having fits, blackouts and other adverse symptoms, and in some instances multiple 
ambulances had been required when several prisoners had needed assistance at the same 
time. This not only put individual prisoners at risk, but also placed an excessive demand on 
resources that were required for the local community too. Prisoners and staff in more than 
one establishment used the term ‘mambulance’ to refer to ambulances called specifically to 
deal with people who had used ‘Mamba’. 
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3.54 Illicit drug use is also linked to deaths in custody. The Prisons and Probation Ombudsman 
(PPO) reported in 2011–12 that 6% of all fatal incidents15 that he investigated were due to 
drug toxicity. Recurring factors in these deaths included trading in prescribed or smuggled 
drugs, the hoarding of drugs for later use and the combined effects of prescribed medication 
and illicit drug use (PPO, 2012a). The PPO highlighted in July 2015 that in 19 deaths in prison 
between April 2012 and September 2014, the prisoner was known, or strongly suspected, to 
have been using NPS-type drugs before their deaths (PPO, 2015). The report noted that 
there was a link between the use of NPS and both mental and physical health problems. The 
PPO has reported that NPS have altered prisoners’ behaviour, and highlighted the health 
risks, along with debt and bullying, resulting from their use, creating the potential to increase 
self-harm and suicide among vulnerable prisoners. 
 
 
 
15 The total of 229 includes four deaths in immigration removal centres and 15 in probation approved premises, the 
remainder being in prisons. 
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Section 4. Service responses 
A whole-prison approach 
4.1 All prisons have to hold prisoners securely, reduce the risk of reoffending and provide safe 
and well-ordered establishments in which prisoners are treated humanely, decently and 
lawfully. There is therefore a continuous challenge to maintain the right balance between 
security, care and rehabilitation. 
4.2 The need for a whole-prison approach to drug and alcohol issues is clear from the Prisons 
and Probation Ombudsman (PPO) 2011–12 annual report (PPO, 2012a) conclusions that the 
following improvements were required to reduce prison drug fatalities: 
 
 Reviewing the medications prescribed to prisoners with known drug habits 
 
 Improving information sharing between prison prescribers, to ensure that prisoners are 
not prescribed medication which can be fatal when taken together 
 
 Reducing the supply and use of illicit drugs within prison. 
 
What is a whole-prison approach to substance misuse? 
 
A ‘whole-prison’ approach requires coordinated activity across prison departments to tackle three 
broad areas:  
 
 Supply reduction: stopping drugs getting into the prison  
 Demand reduction: reducing the demand for drugs by addressing wider issues that may lead 
to drug use. For example:  
i. Action to reduce violence and bullying – when prisoners feel safe in custody they 
experience lower levels of stress, and the desire to self-medicate will be reduced 
ii. Provision of adequate purposeful activity to reduce boredom and promote better sleep 
patterns  
iii. Provide timely access to health services, including effective pain management, dental 
care and external hospital appointments, reducing the demand for self-medication  
 Treatment for drug and alcohol issues – this should include timely individualised substitute 
prescribing integrated with evidence-based psychosocial interventions. This should include 
harm reduction measures, including accurate and effective drugs awareness and education 
that equips staff and prisoners to deal with situations and make informed choices in their 
own behaviour. 
 
This should be supported by broader prison characteristics, including a rehabilitative culture, effective 
staff–prisoner relationships, a decent environment and proportionate security measures.  
 
4.3 Effectiveness begins with establishing the level of need efficiently and promptly, to ensure 
that the prison devotes sufficient and appropriate resources to meeting that need – be it 
drug testing, searching, training or treatment, or the appropriate combination of all of these. 
Initially, many prisons were slow to respond to the rapidly changing landscape in relation to 
synthetic cannabis. Some prisons responded well to the challenge but others did not, and this 
was exacerbated by an initial lack of national guidance to prisons to help them to manage this 
problem and share good practice. The National Offender Management Service (NOMS) 
published guidance in February 2015, which reminded governors of the existing powers that 
they had, such as imposing sanctions for finds of alleged new psychoactive substances (NPS) 
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as an ‘unauthorised article’ rather than waiting to get it tested. Public Health England is 
preparing a toolkit on NPS for use in prisons which is due for publication in Autumn 2015. 
Joint guidance from NOMS and Public Health England earlier would have helped to establish 
the coordinated approaches required. 
4.4 The Blakey report (2008) on supply reduction in prisons reported on inconsistent 
integration between operations, security and treatment, and said: 
‘I would have liked to have found in every prison a clear and consistent arrangement for running 
the drug strategy covering both treatment and trafficking and headed by a senior governor’.  
4.5 In inspection reports published between April 2014 and August 2015, we identified several 
prisons which had an excellent strategic, whole-prison approach to drug and alcohol issues. 
However, in too many adult prisons the strategy was out of date, had no accompanying 
action plan or lacked a current underpinning needs assessment. 
 
The prison’s strategic approach to drug and alcohol treatment was among the best we have seen. The drug 
strategy governor and partnership manager worked closely together to oversee delivery of what was called the 
prisoner's 'recovery journey'. This could include clinical care and a wide range of low-, medium- and high-
intensity psychosocial interventions and aftercare. The combined treatment and supply reduction strategy was 
delivered through a very comprehensive action plan, which was monitored by a well-attended drug strategy 
committee. HMP Northumberland 2014 
4.6 Some prisons we inspected used out-of-date or insufficient information for their needs 
assessment – for example, only using data from drug services and ignoring potentially rich 
data from other sources, including health reception screens, prescribing trends, prisoner 
feedback, offender assessment system (OASys) data, drug finds and mandatory drug testing 
(MDT) testing results. Patterns of drug use can change quickly and regular systematic review 
of local prisoner needs is essential for an effective strategy. 
4.7 An effective substance misuse committee is integral to the successful implementation and 
monitoring of a prison’s drug and alcohol strategy. However, in several prisons we inspected 
in 2014–15, poor attendance by representatives of key departments, such as security, health 
services, offender management unit and residential managers, or an insufficient strategic 
focus reduced its effectiveness. This was further exacerbated in some prisons when 
substance misuse was subsumed into other committees, such as resettlement, without 
ensuring that an adequate strategic focus on substance misuse was maintained. 
How drugs get into prison? 
4.8 It is not possible to estimate accurately the extent of drug trafficking into prisons. However, 
drugs are clearly getting into prisons, and medications that are prescribed within prisons are 
being diverted, as evidenced by intelligence reports, positive drug testing and drug finds. 
Supply arrangements are often sophisticated and supply routes are likely to reflect the nature 
of the prison and the physical attributes of the drug itself. In any prison, illicit mobile 
telephones can be used to organise supply. 
4.9 The Blakey report (2008) highlighted that visitors, ‘over the wall’, post, prisoners and staff 
were the primary sources of illicit drugs. 
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Visitors 
4.10 Prisons are busy environments that, by necessity, have large numbers of visitors. This 
includes social visits for prisoners from family and friends; professional visits, including 
solicitors, health professionals, probation officers and community drug workers; prisoner 
transport vehicles; and assorted contractors, food deliveries and so on. There are 
mechanisms in place to search people and vehicles visiting prisons and to oversee activity to 
reduce opportunities to smuggle contraband in and out. However, manual searches cannot 
detect substances that have been swallowed or concealed internally. Table 1 shows the 
number of incidents where visitors were arrested by the police on suspicion of conveying 
drugs into prisons in England between April 2011 and March 2014. 
 
Table 1: Number of incidents where visitors were arrested by the police on suspicion of 
conveying drugs into prisons in England, April 2011 to March 2014 (Hansard, 2015) 
 
 2010–11 2011–12 2012–13 2013–14 
Total 268 229 248 296 
‘Over the wall’ 
4.11 Some prisons are vulnerable to throwovers (items coming over the wall). This may be due to 
having a long perimeter that cannot be monitored effectively at all times or being located on 
a main road or in a housing estate where people outside the prison can access it easily. Items 
thrown over have included tennis balls, dead birds or small animals stuffed with drugs, which 
can then be picked up by prisoners (see Figure 9). Prisons have also reported arrows being 
shot into the prison with a line attached to pass items, and large catapults to carry drugs 
over perimeter walls (see Figure 10); drones have also been captured in some prisons. 
Category C training prisons, which have large perimeters and relatively free prisoner 
movement as they go to and from work, are most susceptible to drugs coming over the wall.  
 
Figure 9: Drugs found in one prison which had been projected over the fence in tennis 
balls and packages weighted with coins 
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Figure 10: Catapult found outside a prison fence, used to project contraband into the 
prison 
 
 
  
 
Post 
4.12 Drugs may be secreted in items posted to the prison, including trainers and children’s 
artwork. Synthetic cannabis is very versatile and can be sprayed onto paper – letters or 
documents posted to a prisoner, for instance – and then smoked as part of a roll-up 
cigarette. There were 349 reported incidents in which drugs were discovered in prison post 
in England and Wales in 2013–14 (Centre for Social Justice, 2015).  
Prisoners 
4.13 New arrivals into prison may arrive with drugs secreted on or in their person for personal 
use or wider distribution, or as couriers for others; this is most likely to happen in local 
prisons, which have a high prisoner throughput. We have been told of offenders breaching 
their licence deliberately to be returned to prison for a short period so that they can take 
drugs in; they may be paid large amounts of money to do this. All prisoners are given a rub 
down search on arrival in prison, and they may be scanned or strip-searched by officers, 
based on identified risk. However, some drugs that are secreted internally cannot be 
detected, so drugs are able to enter the prison in this way.  
Staff 
4.14 People who work in prisons, and particularly those who have keys, have high levels of 
freedom around the establishment. Staff may agree to bring in contraband for profit or 
because they have been coerced or threatened. In prisons with high levels of security, staff 
may also facilitate smuggling by drug couriers such as visitors, by helping them to avoid 
security checks. Strategies to address staff corruption include stringent security checks on 
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staff before they start work at the establishment, targeted and random staff searches, and 
training to avoid conditioning, although this does not prevent corruption (see Table 2). 
 
Table 2: Number of staff convicted, dismissed and excluded in relation to conveying 
drugs into prisons in England, April 2011 to March 2014 (Hansard, 2015) 
 
 2010–11 2011–12 2012–13 2013–14 
Total 11 16 9 25 
4.15 Any of the above-named routes, and more, may be used in any prison and there are no 
reliable data to show which is most prevalent. Nevertheless, it is clear that supply routes will 
respond quickly to weaknesses in defences and changes in profit factors, which means that 
security measures should be equally responsive. 
4.16 In HMI Prisons inspection reports published between April 2014 and August 2015, 35% of 
male and 28% of female prisoners surveyed said that it was easy or very easy to get illegal 
drugs in the prison they were in. There was wide variation between different types of prison, 
ranging from a low of 18% in high secure establishments to a high of 41% in category C 
training prisons. This finding is, of course, an indication of perceived rather than actual 
availability; however, we have consistently found the most prominent reported issues 
relating to drug supply and misuse to be at category C training prisons. 
4.17 The number of incidents in which drugs have been found in a prisoner’s possession in 
prisons in England has increased over the past four years (see Table 3). 
 
Table 3: Number of incidents in which drugs were found in a prisoner's possession in 
prisons in England, April 2011 to March 2014 (Hansard, 2015) 
 
 2010–11 2011–12 2012–13 2013–14 
Total 1,163 1,211 1,545 1,694 
4.18 NOMS is working with the Home Office on legislation to tackle drug supply across the UK. 
Work is also under way on developing new drug tests for NPS, strengthening perimeter 
defences, producing a new generation of body scanners and training drug dogs to detect 
NPS, along with working with the police and Crown Prosecution Service. A clause has been 
included in the Serious Crime Bill which, if agreed, will create an offence of throwing or 
projecting any item over a prison perimeter so that it lands in a prison. NOMS is also 
working with NHS England on updated clinical guidance on the management of substance 
misuse in adult prisons and providing an NPS toolkit for prisons.  
Supply reduction 
4.19 The Blakey report (2008) highlighted that the way to disrupt supply routes into prisons was 
to: 
 Use good practice 
 Disrupt the use of mobile telephones 
 Use searching 
 Use search dogs 
 Use legislation 
 Develop and use technology 
 Develop partnership working with the police 
 Use intelligence. 
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4.20 All of the above remain central to effective drug supply reduction in prisons. NOMS further 
highlighted the challenge (NOMS, 2009):  
‘There is growing evidence of carefully organised attempts to traffic drugs into prisons, with great 
efforts made by criminals to overcome improved security measures in order to exploit the 
potential profits to be made in doing so. Reducing prison drug supply is a constant battle. As one 
route is closed, it does not take long for another to open’. 
4.21 There is certainly no evidence to suggest that the threat has diminished – and the rapid 
increase in the availability of synthetic cannabis may indicate that it has increased. 
Strategy 
4.22 Supply reduction is a key component of prison activity to maintain safety and security, and 
starts with an effective strategy. The HMI Prisons 2014–15 annual report noted that too 
many prisons had an inadequate supply reduction strategy; many were out of date, lacked 
clear actions, were not regularly reviewed and did not adequately reflect key issues 
(including NPS and medication), and frontline staff were often not aware of the key priorities 
(HM Inspectorate of Prisons, 2015). This will inevitably lead to an inadequate response. 
4.23 Supply reduction in prisons requires coordinated, integrated working between all prison 
departments, including security, residential units and health care, as each have an interlinking 
role to play in supply reduction. We have seen effective multi-departmental approaches to 
reducing drug and alcohol supply at several prisons. However, strategies in some prisons 
were weakened by ineffective communication of key priorities to operational staff, which 
meant that the strategy was not translated into action. Despite the number of problems 
associated with synthetic cannabis, we are still finding that most prisons do not have an 
explicit NPS supply reduction strategy, although some prisons do have good strategies. 
 
Key departments were represented at the monthly security meeting and relevant longer-term objectives were 
set to reflect threats relating to drugs, mobile telephones and items that were being thrown over the fence. A 
weekly intelligence meeting with security and other relevant staff reviewed all incidents and identified actions, 
which were followed up. A daily security briefing was distributed among all staff and we observed wing 
managers carrying out detailed briefings on the wings. The prison received good support from local police and 
there were adequate anti-corruption procedures in place. HMP Dovegate 2015 
 
There had been several serious incidents over the previous few months, many of which had been attributed to 
NPS. The security department was sighted on the threats and issues of NPS supply, and had introduced 
several specific initiatives, a committee and an action plan to address these … However, since the absorption 
of the drug strategy committee into the quarterly reducing reoffending meeting, a whole-prison approach to 
drugs had only been achieved with the recent introduction of an NPS committee. Only one such meeting had 
been held but a dynamic action plan was emerging and there was a renewed strategic approach involving all 
relevant departments. HMP Stocken 2015 
 
Key departments were represented at the monthly security meeting and relevant longer-term objectives were 
set to reflect the current threats around drugs, gang issues and mobile telephones. There were good 
relationships with other departments, particularly safer custody, with effective exchange of information 
between these departments. The prison received some support from the local police and also from the North-
West region Titan team, which provided police support for security and anti-corruption matters. … There had 
been increasingly regular and large finds of NPS, coupled with several reported instances of prisoners 
presenting with the effects of having taken these, some of which had been reported as being Spice... The 
prison was dealing with the issue robustly through a specific strategy which included the education of 
prisoners and staff, and a clear protocol for dealing with prisoners suspected of taking these substances. 
HMP Liverpool 2015 
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Searching and finds 
4.24 As discussed above, drugs can enter prisons in many ways, so supply reduction approaches 
need to address all these routes in a proportionate way. Searching, both routine and 
intelligence led, is an important supply reduction tool. Searches may be made of prisoners, 
staff, visitors, prisoner property and the prison itself, and can be random or intelligence led.  
4.25 Finds may be of drugs and associated paraphernalia (such as foil or syringes), medication or 
mobile telephones, which may be used to set up drug deals. The level of drug finds alone 
does not accurately reflect the level of use as it is unlikely that all illicit drugs will be found; 
however, in combination with other measures, including MDT rates, levels of violence and 
intelligence, it may indicate the effectiveness of supply reduction measures. We have 
repeatedly found on inspection that intelligence-led searching was either very delayed or did 
not occur, often because of reduced staffing levels. 
 
In the previous six months, 2,099 intelligence reports had been submitted and processed efficiently, but some 
necessary actions, including target searching, were not always completed within acceptable timescales. 
Despite this, there had been some good finds, including ‘hooch’ (illicitly brewed alcohol), drugs, mobile 
telephones and weapons (mostly in communal areas), but prisoners and staff indicated that such items 
continued to be available. The main challenge was the prevention of unauthorised items, including mobile 
telephones, illegal drugs and new psychoactive substances (NPS). The security department worked well with 
other departments and external agencies, including the police, and was focused primarily on drug- and debt-
related issues. The prison was active in trying to address these issues in a measured and proportionate way, 
but more was required as prisoners continued to be exposed to the associated violence. HMP Stoke Heath 
2015 
4.26 Synthetic cannabis has no distinctive odour and is therefore harder to detect than non-
synthetic cannabis, making it more attractive to smuggle in and use. The penalties for a 
prisoner caught with synthetic cannabis or other NPS will usually be limited to 'possession of 
an unauthorised article' as they have not been identified officially by drug testing The penalty 
will be lower than for 'possession of a controlled drug', increasing the attractiveness of 
synthetic cannabis to users and dealers. However, the supply reduction policy at HMP 
Stocken (2015) appropriately included enhanced penalties for possession of NPS, to act as a 
deterrent.  
4.27 Dogs trained to detect the smell of various substances, including drugs and mobile 
telephones, are deployed in some prisons and can be useful both in increasing finds and 
acting as a deterrent to use. Some staff interviewed for this thematic inspection said that 
drug dogs were a valuable resource, but there were not enough of them and they were not 
trained to detect new drugs such as Spice or other NPS. Currently, few prisons have access 
to dogs trained to detect Spice, although more are now being trained (NOMS, 2015b). 
4.28 Figures from the Ministry of Justice16 show that the number of Spice finds in prison increased 
markedly, from 15 in 2010 to 262 in 2013, and then again to 430 (an increase of 60%) in only 
the first seven months of 2014, the latest year for which information is available. It is unclear 
from this if these finds were all confirmed as Spice by drug analysis. Our inspectors are often 
told about finds of unidentified tablets or herbal matter. It is essential that finds are analysed 
to establish what drugs are being found, to inform an effective local drug strategy. 
                                                                                                                                                                                     
16 www.gov.uk/government/news/new-crackdown-on-dangerous-legal-highs-in-prison [accessed 7 December 2015]. 
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MDT  
4.29 Prison MDT identifies how many of those who have been targeted for a test used one of the 
substances on the testing panel in the days preceding the test. However, prisoners may have 
used substances that are not tested for, or used substances that are tested for but not in the 
days immediately before the test, so MDT is not an accurate reflection of drug use in prison. 
 
MDT 
The MDT programme has been in place since 1996 to supply information on patterns of drugs 
misuse, deter prisoners from misusing drugs, identify those in need of referral to drug treatment, 
contribute to drug supply reduction, and contribute to prisoner safety, violence reduction, order and 
control (Ministry of Justice (MOJ), 2015). There is clear guidance on how MDT is to be conducted 
(MOJ, 2005). Currently, MDT can only test for drugs that are controlled substances under the 
Misuse of Drugs Act (1971), so cannot test for many medications or NPS.17 
 
There are five types of MDT: 
 
Random testing: This involves prisoners being selected for testing on a strictly random basis. 
Establishments with an average population of 400 or more in the previous 12 months must test at 
least 5% of their population, and those with fewer than 400 at least 10% monthly. At least 14% of 
random tests must be carried out at weekends. All prisoners appearing on the main random list must 
be tested, unless they have been discharged or are excused by health services staff. Each prison has 
its own random MDT target, agreed with the area manager. Testing should be unpredictable and 
spread evenly across the month.  
 
Suspicion testing: This involves prisoners being tested because staff have reason to believe that 
they have misused drugs. A decision to authorise the test should be made on the basis of analysis of 
the intelligence received and should be completed within 72 hours of the intelligence being 
submitted.  
 
Frequent testing: All prisoners found guilty on adjudication of taking a Class A drug, such as 
cocaine, must be placed on a programme of frequent testing, although the number, frequency and 
period of frequent testing is at the governor’s discretion. Frequent testing can be considered for 
other drug offences, and appropriate support for drug misuse should also be offered. 
 
Reception testing: This may be completed on reception to a prison, either as a transfer between 
prisons or on first arrival to prison from the community, on a routine or occasional basis  
 
Risk assessment: This involves testing because a prisoner is being considered for a privilege, a job 
or a situation where a high level of trust is to be granted. This may include release on temporary 
licence or reclassification. The testing should be completed without prior warning and be as 
unpredictable as possible. Once selected, prisoners are required to provide a urine sample, which is 
sent to a laboratory for testing. Prisoners who either test positive for a drug that has not been 
prescribed legitimately or refuse to be tested are punished under the prison discipline (adjudication) 
system. Prisoners who test positive are automatically referred to prison drug treatment services.  
 
Drug detection time in the urine 
 
The length of time for which different drugs can be detected in urine varies by drug and individual 
factors, such as level of use and metabolism; for example, detection times for cannabis vary from 
three days for a single use to 36 days for heavy daily use, and for heroin are around 24 hours.   
 
 
                                                                                                                                                                                     
17 Processes are under way to insert a clause into the Prisons Act 1952 to allow prisons to be tested for drugs that are not 
controlled under the 1971 Act in England and Wales. 
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4.30 Figures from NOMS show that positive random MDT rates have reduced, from a mean of 
24.4% across all prisons in 1996–97 to 6.9% in 2014–15. They have been steady over the past 
three years, at around 7% (NOMS, 2014a). The positive random MDT rate between April 
2014 and March 2015 dropped overall, from 7.4% in the previous year to 6.9%, but increased 
in some establishments, including women’s closed and women’s local prisons (NOMS, 
2015c). Men’s local prisons had the highest positive rates. The results for individual prisons 
ranged from a low of 0.2% at HMP Ashfield to a high of 19.1% at HMP Pentonville (NOMS, 
2015d). 
4.31 MDT can be a useful indicator and deterrent, if used effectively. However, the past two HMI 
Prisons annual reports highlighted that some prisons do not meet their random MDT 
targets, and that in a large proportion of prisons significant numbers of MDT suspicion tests 
are either not done or completed out of time (HM Chief Inspector of Prisons for England 
and Wales, 2014, 2015). The value of MDT is further undermined by the increased use of 
undetectable drugs and medicines that are not on the testing panel, such as most 
medications and NPS. The Criminal Justice and Courts Act 2015 will, in time, allow prisons 
to test for a wider range of substances under MDT, which will be a welcome initiative. MDT 
is a useful aspect of supply reduction but the figures for a prison should not be used as a 
measure of its current performance, as they may give false assurance or encourage a focus 
on drugs on the MDT panel, at the expense of other, equally harmful substances.   
 
Mandatory drug testing (MDT) rates were higher than the target (6.8% against 4.5%), and in our survey, 
more prisoners than the comparator said they had developed a problem with drugs in the prison. 
Nevertheless, the prison’s strategic approach to drug supply reduction was well-sighted on the most common 
entry routes, and had achieved some good success with drug finds. The prison used drug dogs trained to 
detect the new psychoactive substances (NPS), and staff and prisoners’ knowledge of the dangers of these 
drugs was improving through an effective awareness raising campaign. Although suspicion drug tests were 
unable to detect NPS, they were timely. Cannabis was the main drug detected under MDT. HMP Brinsford 
2015 
 
The prison had implemented a frequent testing programme and multi-agency case reviews as part of the 
support and sanctions protocol, and information sharing between security and substance misuse services was 
good. This strategy combined punitive measures for those found using illicit substances, with a clear support 
plan. We felt it provided a robust response to the challenges faced, and sent a clear message that the use of 
illicit drugs would not be tolerated, while still offering appropriate support. HMP New Hall 2015 
Sanctions for prisoners found to be involved in illicit substance misuse in 
prisons 
4.32 Prisoners found to have been involved in using or distributing illicit drugs in prison may be 
sanctioned in a variety of ways, depending on the severity of the offence. A history of 
negative sanctions will have an impact on sentence management decisions, including 
recategorisation. 
Incentives and earned privileges (IEP) 
4.33 In the IEP scheme, which was introduced in 1995, prisoners have the potential to earn 
privileges through demonstrating positive behaviour, and to lose privileges through negative 
behaviour, such as the use of illicit substances. Privileges may include association time, 
additional access to gym facilities or the amount that can be spent in the prison shop. 
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Adjudication 
4.34 When a prisoner breaks a prison rule, he/she can be charged with an offence against the 
prison rules (NOMS, 2011). The charge has to be laid within 48 hours of the offence and be 
heard the next day by a governor. If the charge is serious, it could be referred to the police 
or to the independent adjudicator.18 There are clear rules governing how this process is to 
be managed and how the prisoners can defend themselves against the charge. If the charge is 
proven, a sanction (punishment) will be allocated which must comply with the Prison Rules 
(1999) and may include exclusion from work, cellular confinement for a specified period or 
stoppage of pay. 
Closed visits 
4.35 Social visits from family or friends are an important part of the rehabilitation of prisoners and 
are essential to maintaining good family ties. However, social visits are a known potential 
route by which illicit items, including drugs, can be smuggled in. The management of visits is 
governed by security rules and guidance to maintain prison security. Specific visitors may be 
banned for a specified period or closed visits may be put in place.  
4.36 Closed visits19 can be an effective and proportionate response to suspected trafficking 
through preventing direct contact between a prisoner and his or her visitor(s). There is a 
balance between ensuring that prisoners and their families have good-quality visits, that 
prisoners’ families and children are treated decently and that healthy relationships are 
encouraged – and ensuring adequate security to prevent trafficking.  
Preventing the misuse of diverted medication 
4.37 In the HMI Prisons 2012–13 Annual Report (HM Chief Inspector of Prisons for England and 
Wales, 2013), we stated: 
 
In many prisons inspected, several factors contributed to medication diversion – high levels of prescribing of 
medications liable to abuse; divertible medication inappropriately given to prisoners in possession; poor 
supervision of medication queues; and a lack of secure in-cell storage for medications. In several prisons, the 
strategic approach to the problem was poor. HM Chief Inspector of Prisons Annual Report 2012–
13 
4.38 In high security prisons, a high level of external security may make diverted medication the 
easiest drug to obtain. 
Strategy 
4.39 Efforts to address the diversion of medication prescribed in prisons should be included in the 
prison’s strategic approach to drugs and alcohol, and include good prescribing practices, 
administration and queue supervision; the secure in-cell storage of in-possession 
medication;20 and the use of spot checks to assess if prisoners prescribed medication in 
possession are using them appropriately. A range of general and prison-specific prescribing 
guidance exists to inform best practice. Inspections over the past two years found that 
prescribing practice had improved, but it remained an issue in a significant minority of 
                                                                                                                                                                                     
18 Independent adjudicators are district judges or deputy district judges approved by the Lord Chancellor for the purpose 
of enquiring into the charges referred to them. 
19 Closed visits involve a prisoner and visitor(s) being separated by glass and unable to make physical contact. They are 
usually applied as a result of attempting to smuggle unauthorised articles into the prison through visits. 
20 When a prisoner receives medication ‘in possession’ they are permitted to keep it in their cell. 
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establishments, often exacerbated by high use of locum prescribers who did not follow the 
available guidance. The implementation of a tradable medication strategy based on cross-
departmental cooperation had reduced the misuse of tradable prescription medication at 
HMP Wakefield (2014). 
In-possession medication 
4.40 In-possession medication increases prisoner autonomy, prepares them to manage their own 
medication on release and allows them to take their doses at appropriate times. It also 
reduces the risks – for example, bullying – associated with excessively long medication 
queues. There are also potential advantages for the establishment in reducing the time 
required for drug administration – which is even more crucial, given the recent changes to 
the core day that leave little time for this. However, the decision to give medication in-
possession has to be based on an individual current risk assessment that considers the risks 
associated with both the individual and the drug(s). 
4.41 Of the 61 adult prison reports published between April 2014 and August 2015, we 
highlighted that five establishments had an inadequate in-possession policy, 14 needed to 
improve their risk assessment processes and seven did not provide prisoners with secure 
storage for in-possession medication.  
Administration 
4.42 Prisoners assessed to be at high risk of overdosing are given their medication under 
supervision. Additionally, medication that is deemed to have a high potential for diversion 
may be administered under supervision, regardless of the individual’s assessed risk. 
Supervised medication requires prisoners to take their medication in front of a nurse and 
demonstrate that it has been swallowed by showing that no medication is secreted in their 
mouth or hands. Medication queues can offer opportunities for bullying of other prisoners, 
breaches of confidentiality by crowding around the administration area, intimidation of health 
services staff and diversion of medication. The presence of discipline staff at medication 
administration queues can prevent these issues and is a key aspect of supply and violence 
reduction. However, we are finding that it is increasingly common for there to be 
inconsistent or no observation of medication queues by discipline staff, usually because of 
reduced staffing levels. 
4.43 In our survey for this thematic inspection, 4% of respondents said that they had previously 
given away or traded their own prescribed medication and 9% that they had been pressured 
to give it away: 
‘I have been hassled for meds; people come up to me and try to get me to sell, but I won’t as I 
need them. Getting meds at the hatch is a problem as people can see and hear what other 
prisoners are getting. They could dispense when everyone is locked up instead’. 
4.44 Others we interviewed said that they had chosen not to be prescribed specific medication in 
order to avoid being pressured to give it away: 
‘As soon as I came to F and A wings, I was asked what medication I was taking. I felt intimidated 
but not threatened; it was frightening at the time due to my mental health issues but I was too 
scared to ask for daily meds as they may put me on an ACCT21 because I overdosed in the past. 
Getting weekly meds in possession was a contributing factor to coming off my anti-psychotics – 
avoid the hassle of people asking for meds’. 
 
21 Assessment, care in custody and teamwork case management for prisoners at risk of suicide or self-harm.  
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Some prisoners reported feeling anxious in health care or trying to be last in the queue at the hatch because 
they were scared of other prisoners knowing what medication they had been prescribed in case it was taken 
off them. In the previous six months, 60 to 70 patients had been on opiate substitution therapy, with an 
average of 61% on reducing regimes, which was appropriate. Prescribing and care were robust and recovery 
focused, with reviews at appropriate intervals. The administration of opiate substitution medication was safe. 
… officers sited themselves strategically and regulated medicine queues. Patients had confidentiality, were not 
subject to intimidation, and staff took time and care to check that medications had been ingested. Health 
care offered 24-hour nursing care for patients undergoing detoxification. There was no drug-free area in the 
prison, which presented a daily challenge for those preferring abstinence. HMP Altcourse 2014 
4.45 Some prisoners will try to take their medication away with them; sometimes, this is because 
they want to take it later because the timing of administration is inappropriate. In 12 of the 
61 HMI Prisons reports published between April 2014 and August 2015, we highlighted 
concerns that the timing of medication administration was inappropriate, including night 
sedation being given as early as 4.30pm. 
4.46 Prisoners may also want to take their medication away with them to divert or pass it on to 
others for personal gain or as a result of coercion. This can include regurgitation of 
medication, both in tablet and liquid form, for other prisoners to take. Supervision of supply 
is therefore essential for all medication. We observe the administration of medication as part 
of each inspection, and in some establishments we have seen chaotic, unsupervised and 
sometimes unhygienic administration practices, which exacerbate the risks of medication 
being diverted. Of the 61 adult prison inspection reports published between April 2014 and 
August 2015, inadequate officer supervision of controlled drug administration was highlighted 
for six prisons, and of general medication in 20 prisons. 
Pain management 
4.47 Effective pain management is a complex issue as pain can be difficult to assess objectively; this 
complexity is exacerbated in prisons (Public Health England, 2013a). Many prisoners have a 
history of injuries, broken bones and chronic back pain. Anxiety related to imprisonment, 
and aspects of the prison environment such as reduced access to exercise and poor-quality 
beds, can also intensify symptoms. Accessing treatment for drug misuse can result in a 
resurgence of pain that was previously masked by the illicit drug as its pain-relieving effect 
wears off. Additionally, illicit drug use is no longer the focus of every day, so that the 
individual is able to address other issues they have put off, such as relationships, medical 
issues and finances. Some prisoners arrive in prison on extensive, complicated prescribing 
regimes, including medications that have not been prescribed in line with best clinical 
practice. This creates significant challenges for prescribers to identify those with genuine 
need and to ensure that prescribing is correct. NHS England is developing a national pain 
formulary for use across the secure estate which addresses the unique challenges presented 
by the prison environment; it is due for publication in late 2015 and will supplement the 
current guidance (Department of Health, 2007; Public Health England, 2013a). The Royal 
College of Anaesthetists and Public Health England have been running joint training events on 
pain management in prisons since July 2015. 
4.48 Some prisoners have genuine chronic severe pain but others may be motivated to use old 
injuries to seek prescribed medication to alter their mood or to sell. We spoke to prisoners 
who confirmed that faking pain was an accepted conventional method of obtaining 
medication to sell on. 
4.49 HMI Prisons reports published between April 2014 and August 2015 identified inconsistent 
management of pain across the prison estate, with some prisons refusing to prescribe certain 
medications, such as tramadol and pregabalin because they have a high potential to be 
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diverted. This may seem to be an easy and desirable solution for managing high-value 
tradable items. However, it does not give prisoners community-equivalent care, and 
generates significant physical and mental distress for those who are denied medication; for 
example, some prisoners interviewed for this thematic inspection described having to endure 
high levels of pain as a result of being denied pain relief. It also creates additional risks, 
including an underground market for the drug.  
4.50 Pharmacological treatment is only part of the solution for persistent pain, and the support 
available needs to include broader approaches, including psychologically informed 
interventions and physical rehabilitation. Some prisons use a multidisciplinary approach 
including pain specialists to ensure that the management of pain is evidence based and 
effective, including relevant non-pharmacological strategies, according to best practice.  
NPS: Education and awareness-raising 
4.51 We observed a mainly poor level of awareness of synthetic cannabis among prisoners and 
prison staff in HMI Prisons inspections between April 2014 and August 2015. Some staff we 
interviewed for this thematic inspection said that prisons should do more to train staff in 
how to deal better with NPS incidents on a local area or national basis. Staff training in some 
prisons where NPS are a problem has often been difficult to organise as staff shortages have 
reduced opportunities to release staff from operational duties to attend training sessions. 
4.52 Prisoners we interviewed also said that they would have liked to be taught about NPS on 
arrival into the prison. We have seen effective targeted initiatives at some prisons. HMP 
Dovegate (2015) prisoner peer workers facilitated an education session for all new 
receptions, including a DVD on NPS, which we judged to have reduced the number of NPS-
related incidents in the prison. 
 
Survey results and an average mandatory drug testing (MDT) rate of 13.6% for the main prison in the 
previous six months indicated that drugs were widely available, and 41% of prisoners told us it was easy to 
get drugs in the prison. Finds were mainly for subutex, NPS and hooch. The prison was taking steps to 
address NPS use, including producing a DVD which showed the negative health effects of using these 
substances, which was being routinely shown to prisoners. HMP Dovegate 2015 
 
The positive random mandatory drug testing (MDT) rate for the six months to May 2014 was relatively low, 
at 4.8%, against a key performance target of 6.0%. However, this did not accurately reflect drug usage as 
there were large-scale issues with ‘Spice’ and diverted medication, which could not be detected by the current 
MDT testing panel. In the previous six months, there had been 15 acute incidents where prisoners' use of 
Spice had been suspected, three of which had resulted in prisoners being taken to hospital. In response to 
this, the drug strategy committee had coordinated a series of well-organised initiatives, including the provision 
of information on the dangers of Spice to staff, prisoners and visitors. In the same period, staff had requested 
173 tests on prisoners suspected of taking drugs, but very few of these (only 30%) had been completed 
because of the redeployment of testing staff. HMP Wymott 2014 
 
The mandatory drug testing (MDT) positive rate was 4.5%, which was lower than target (10%) and than at 
the time of the previous inspection, but prisoners and staff told us that this was not a true reflection of drug 
use, owing to the availability of ‘Black Mamba’ (a new psychoactive substance), which was not detectable. 
Staff had found 23 packages thrown over the wall in the previous six months, most of which had been 
believed to contain Black Mamba. In November 2014, the supply reduction strategy had been updated to try 
to address the availability of Black Mamba, initially through close working with the police and education for 
prisoners and staff. HMP Oakwood 2014  
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4.53 We have also seen some effective peer-led education, whereby well-trained and well-
supervised prisoners provided effective education to other prisoners, such as at HMP High 
Down (2015). 
 
The security committee set and monitored appropriate objectives focused on maintaining a safe environment. 
Intelligence was mostly processed efficiently. The average positive mandatory drug testing (MDT) rate was 
low, at approximately 6%. We were told that new psychoactive substances (highly potent synthetic 
cannabinoids that are potentially more harmful than cannabis but do not show up in MDTs) had been a 
problem in the prison but their use appeared to be diminishing. Peer mentors were used well to make 
prisoners aware of the risks of NPS. HMP High Down 2015 
4.54 Prisoners’ families and friends can be both a source of positive support and a potential route 
by which drugs can come into prison. We have found little evidence of efforts to educate 
families and other visitors about the risks they create for prisoners by bringing in drugs 
(especially synthetic cannabis) for them, or to support family members and visitors who may 
be under pressure to do so. In addition, little use has been made of supportive family 
members to work with the prison to encourage prisoners to avoid drug misuse; we have 
seen this in a small number of recent inspections and it appears to be effective. 
4.55 Many prisoners have required emergency medical attention from the ambulance service and 
the local accident and emergency unit. There is a need for evidence-based joint protocols 
and associated training between prisons and their local ambulance services and hospitals to 
ensure that these medical emergencies are managed correctly. 
4.56 The Spice awareness project (see below) highlights both the extent of the issue with Spice in 
that prison and the education work being undertaken to address it. 
Spice awareness project22 
Following a number of overdoses attributed to Spice, a Spice awareness project was undertaken by a 
charity at a large category C prison in November 2014, with the aim of improving Spice awareness 
among staff and prisoners, increasing engagement with drug services and determining the level of 
Spice use within the establishment.  
Every prisoner was interviewed individually on a wing-by-wing basis. Eighty-five per cent of them did 
not know exactly what Spice was, its effects or how to use it safely. Nevertheless, 80% of all 
prisoners said that they had tried Spice during their current sentence, and on some wings around 
65% admitted to using the drug currently. One Spice joint cost £3–4 and gave a day of effect. Regular 
unreported accidental overdoses were described, where the offender concerned was left by others 
to ride it out or placed in the recovery position. The use of ‘drug pigs’ was also common, whereby 
vulnerable prisoners were forced to test new batches of product. 
All wing staff on duty were also interviewed and none of the 50 spoken to knew about Spice, what it 
looked like or how to identify or support users. Information leaflets were distributed to all prisoners 
and left for dissemination to staff.  
Treatment and support services in prison 
4.57 Effective treatment is an important strand of drug supply reduction in prison and is 
undermined if supply reduction strategies are ineffective. Prison provides an opportunity to 
address untreated physical and mental health problems, including addiction. However, this 
                                                                                                                                                                                     
22 Unpublished report shared with HMIP inspectors. 
Section 4. Service responses 
 Changing patterns of substance misuse in adult prisons and service responses 57 
can be difficult to achieve for prisoners on very short sentences or remand, as the individual 
is often released before lasting change can be effected. Substitute prescribing to treat opiate 
addiction can be an important aspect of a wider treatment plan, which should include 
individually tailored psychosocial support. As only a minority of those who access treatment 
will successfully achieve lasting recovery following a single episode of treatment (Strang et al., 
2014), services need to anticipate repeat treatment episodes and the need for ongoing 
(maintenance) prescribing for some, while ensuring that this does not generate complacency 
in treatment provision. 
4.58 Motivation for drug users to enter treatment commonly includes to improve health, end 
their dependence, stop committing crimes, gain employment and take better care of their 
family. Effective treatment requires ongoing work on motivation, plus regular review and 
adjustment, ideally sequencing appropriate care and ensuring access to other services as 
required (Dale-Perera at al., 2014). Public Health England has stressed that, while opiate 
substitution treatment (OST) is an effective intervention for heroin use and dependence, the 
medication itself and accompanying psychosocial/recovery interventions need to be 
optimised to give the user the best chance of recovery and sustained abstinence (PHE, 
2014b).We have observed some inflexible prescribing, enforced reduction and poor 
integration of clinical and psychosocial services in some prisons, contributing to poorer 
outcomes. 
4.59 The services needed in prisons vary between different populations and establishments; for 
example, new arrivals from the community into local prisons will need rapid assessment and 
treatment for withdrawal; those on short sentences or remand need short, focused 
interventions; and those on longer sentences will require longer interventions focused on 
achieving and maintaining recovery. No one approach will meet the needs of all prisoners. 
Furthermore, it is important that prisoners identified with, or suspected of, illicit drug use – 
for example, through finds of unauthorised articles, positive MDT results and behaviour –  
are supported to access treatment. In most prisons we inspected, prisoners who tested 
positive in random MDT were automatically referred to drug treatment services for support, 
but this does not happen consistently when drug misuse is identified in other ways, such as 
finds, which is a missed opportunity. There is potential to use mandated education in 
conjunction with reduced or suspended sanctions, to increase prisoner engagement and 
improve outcomes, in a similar way to drug testing on arrest or the national speed 
awareness scheme (for drivers caught exceeding the road traffic speed limit). 
4.60 In HMI Prisons reports published between April 2014 and August 2015, nearly two-thirds 
(63%) of respondents who said that they had a drug problem reported that they had 
received support for this in the prison they were in, and four in five (80%) said that the 
support had been helpful. Female prisoners were most likely (83%) and men in local prisons 
least likely (59%) to access support. Women were also significantly more likely to report 
that the support they received was helpful (88% compared with 79% in men’s 
establishments).  
4.61 If prisoners develop a drug problem or continue illicit use in prison, it can have an impact on 
levels of violence and debt in prison; it is also likely to affect their rehabilitation and increase 
the likelihood of future offending and further victims after release. The potential for 
prisoners to develop a drug problem in prison is not new. In the Surveying Prisoner Crime 
Reduction study (Light et al., 2013), 55% of heroin users (both male and female) reported 
using heroin in prison, and around 38% of men and 10% of women who reported heroin use 
said that they had started using it in a prison. Although the improvement in prison drug 
misuse services has had a positive impact on the level of opiate use in prisons, diverted 
medication and synthetic cannabis present new challenges. Drug treatment services need to 
be sensitive to changing patterns of use and offer accessible, responsive services. 
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4.62 Prison drug treatment services are not seeing large numbers of prisoners accessing support 
for synthetic cannabis or cannabis, despite our survey of eight establishments for this 
thematic inspection finding that synthetic cannabis was reported by 10% of respondents and 
cannabis by 13%. Not all prisoners who use synthetic cannabis will want, or need, treatment 
but there appears to be a reluctance by prisoners using these substances to engage with 
treatment services. Some prisoners said that they were reluctant to access support because 
they feared being targeted for additional MDT or searches. Others appeared to have little 
knowledge of the drug support services available. Some NPS users expressly stated that they 
had never experienced adverse effects and therefore saw no need for support or treatment. 
At HMP Springhill (2014), prisoner peer supporters ran group support sessions relating to 
NPS, which had led to increased attendance.  
Clinical treatment for drug dependency 
4.63 Prisoners who are dependent on drugs or alcohol are at high risk of complications related to 
withdrawal and treatment in the first five days after arrival in prison. In order to confirm use, 
clinical drug testing is undertaken by health services staff, with the informed consent of the 
prisoner, and this is used to inform clinical management, such as to confirm the need for 
opiate substitute prescribing or to establish if drug use is the cause of particular behaviour or 
symptoms. Clinical testing is also used as part of ongoing opiate substitute treatment, to 
confirm that the prisoner is taking the medication prescribed and is not using illicitly on top 
of that prescription. The results of clinical drug tests are confidential and cannot be disclosed 
outside of the health/substance misuse team without written consent.  
4.64 As part of the care brought in under the integrated drug treatment system (IDTS), all new 
arrivals into local prisons in England are assessed for drug and alcohol withdrawal, and those 
who are physically dependent on opiates should be offered low-dose OST (usually 
methadone). The OST is then gradually increased to a stable dose. Those prisoners who 
arrive already on OST prescribed in the community will usually have it maintained following 
liaison with the community prescriber and pharmacy. Additional monitoring, including 
physical observations, review of levels of withdrawal/intoxication and overnight checks, is 
required during this stabilisation phase.   
4.65 In most prisons we inspect, there are satisfactory arrangements, but there was a significant 
risk of life-threatening consequences at those establishments where monitoring during the 
first five days was inadequate. First night OST was generally available but was either 
inconsistent or absent in a small number of establishments, which increased the risk of illicit 
drug use and adverse physical health consequences. 
 
There was good joint working and information sharing between departments and the integrated substance 
misuse team (ISMT) contributed to sentence planning meetings, HDC, re-categorisation and parole reports. 
Two members of the ISMT also covered local courts, where they started initial assessments and confirmed 
existing treatment regimes. The information was then passed on to the prison-based team to ensure 
treatment continuation. There was evidence of good-quality release planning. The ISMT held weekly pre-
release clinics, where prisoners were provided with harm reduction information; strong links had been 
developed with community-based drug and alcohol services; and local prison link workers visited every week 
to arrange post-release support. HMP Dovegate 2015 
4.66 The UK Government 2010 drug strategy heralded an enhanced recovery agenda for all drugs 
that were misused, including medicines and NPS (known then as ‘legal highs’). It emphasised 
the importance of supporting individuals to access and complete drug treatment successfully 
using both substitute prescribing and other recovery activities (Advisory Council on the 
Misuse of Drugs (ACMD), 2015) rather than maintaining prisoners for long periods on OST 
alone. In English prisons, prisoners on remand or serving short sentences can be maintained 
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on a stable dose of OST if a community service agrees to prescribe and if this is what the 
patient wants, to reduce the risk of accidental overdose post-release due to reduced 
tolerance. Prisoners serving long sentences are generally encouraged to reduce in prison, 
although those with significant mental health or physical health issues may be maintained. 
Both reduction and maintenance should occur as part of a personalised recovery plan which 
includes psychosocial interventions and regular reviews.   
4.67 The HMI Prisons 2011–12 annual report (HM Chief Inspector of Prisons for England and 
Wales, 2012), stated that: 
 
We welcomed a shift in emphasis from long-term methadone maintenance prescribing towards a recovery-
orientated drug treatment approach. HM Chief Inspector of Prisons Annual Report 2011–12  
4.68 However, the annual report in 2012–13 (HM Chief Inspector of Prisons for England and 
Wales, 2013) highlighted that: 
 
In several prisons, there was poor clinical management, ranging from long-term maintenance prescribing 
without regular reviews to forced reduction without sufficient patient involvement, combined with inadequate 
support. HM Chief Inspector of Prisons Annual Report 2012–13 
4.69 Prescribing and psychosocial support need to be optimised to maximise recovery outcomes. 
Strategies associated with rapid abstinence are associated with poor outcomes (Dale-Perera 
et al., 2014), and coercive abstinence in prison may be followed by relapse after release, 
leading to drug emergencies and possibly death (Stover and Michels, 2010).  
4.70 In HMI Prisons reports published between April 2014 and August 2015, most clinical services 
we inspected provided flexible prescribing which included offering both buprenorphine and 
methadone at an appropriate dose for the individual, tailored reduction plans that were 
agreed with the patient, and regular reviews with an appropriate individualised recovery 
focus. Enforced reduction or insufficiently flexible prescribing in some establishments 
contributed to illicit use. Buprenorphine was unavailable or severely restricted in several 
prisons as a strategy to reduce illicit drug use, but this contributed to poorer outcomes for 
some prisoners, particularly those serving short sentences or on remand, who were forced 
to switch from buprenorphine to methadone.  
4.71 Prisoners who achieve abstinence in prison may be vulnerable to relapse, particularly in the 
first few weeks, as they develop alternative coping strategies. The HMP Wymott (2014) 
clinical team provided up to six weeks’ post-detoxification support, which was highly valued 
by prisoners.   
4.72 Support for prisoners with a dual diagnosis (coexisting substance dependency and mental 
health issues) was satisfactory in most establishments, and impressive in HMP Thameside 
(2014), but a few establishments had inadequate provision. In many prisons we inspect, there 
is a divide between prescribing for opiate addiction and prescribing for general health issues, 
including mental health and pain, so prescribing can be uncoordinated and sometimes 
counterproductive. We observed effective joint working at HMP Stocken (2015) between 
mental health, primary care and substance misuse, which we commended as good practice. 
 
 
The support and care coordination of prisoners with substance use and mental health problems had improved 
considerably and a designated social worker, together with a mental health nurse, provided a comprehensive 
new dual diagnosis service … which improved the care of prisoners with substance use and mental health 
problems. HMP Thameside 2014  
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Prisoners of concern were discussed at weekly meetings attended by substance misuse, primary health and 
mental health service senior staff. The identification of prisoners with complex needs was robust and an 
identified care coordinator ensured continuity of care. All health services staff knew who was being managed 
in this way. Case management meetings with other departments were held promptly, to ensure a whole-
prison approach. HMP Stocken 2015 
Psychosocial support23 in prisons 
4.73 Following the transfer of the commissioning of prison substance misuse services in England 
to NHS England, we have seen large variations in psychosocial service provision across the 
different prison-based providers; however, generally, there was an appropriate recovery 
focus for drugs and alcohol in most prisons, and some impressive innovation.  
 
The teams were co-located at the Iris Centre, which had good facilities and offered the 225 women involved 
(more than half the population) easy access. Interventions ranged from low key ‘recovery café’ drop-in 
sessions and evening complementary therapy groups to structured one-to-one work, substance-specific 
modules and a Pillars to Recovery course. Lifeline’s recovery programme ran four times a year and another 
agency, Acorn, provided a 12-week reduction and abstinence recovery programme (RAMP), which was offered 
separately to women with alcohol problems. HMP Styal 2015 
4.74 The substance misuse team in HMP/YOI Isis (2014) was working to engage with vulnerable 
service users, including a new mentoring scheme in relation to gang membership. 
4.75 The introduction of counselling, assessment, referral, advice and throughcare (CARAT), and 
later IDTS, resulted in improved and more consistent support services that were more 
integrated with clinical prescribing services in many, but not all establishments. Since 2006, 
this has developed into a comprehensive package of one-to-one sessions with key workers, 
group-work and self-help fellowships in many English prisons. 
4.76 The integration of clinical and psychosocial services means that prisoners should receive a 
more holistically focused drug treatment service that combines any necessary clinical 
treatment (either at maintenance levels or as a reducing dose) with psychosocial support 
that should ultimately encourage them into recovery and a life free from drugs. HMI Prisons 
Expectations and National Guidelines on the treatment of drug dependence both encourage 
the delivery of integrated services (Department of Health, 2007; HM Inspectorate of Prisons 
Expectations, 2012). Successful treatment outcomes for individuals with substance misuse 
problems are more likely when psychosocial and clinical services work with the client in an 
integrated way. This has been the case in most, but not all adult prisons we have inspected.  
4.77 In several prisons, a shortage of wing staff meant that groups were regularly cancelled and 
that prisoners’ access to valuable peer support was restricted. Prisoners also told us that 
they were unable to access courses as there were insufficient places available. In some 
prisons, only group support was available, which excluded those prisoners who would have 
benefited from one-to-one support.  
4.78 Drug-free residential rehabilitation is a useful option for a significant minority of prisoners 
who need additional support in developing alternative strategies to achieve recovery away 
from their usual environment. We have inspected some excellent drug therapeutic 
                                                                                                                                                                                     
23 Psychosocial support refers to a wide range of interventions that may be offered to help an individual to address physical 
and psychological dependence in addition to any prescribing support. It may include support at different levels of intensity, 
reflecting the severity of the disorder or previous experience of treatment. It can be delivered by staff or peers, as one-to-
one or group sessions. It also often includes practical support and strategies to address social needs or increase confidence 
and build a positive social support network. 
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communities within prisons which offered residents enhanced opportunities to achieve and 
maintain recovery.  
 
Prisoners could also access a drug-free recovery wing, which was similar to a therapeutic community. The unit 
was well managed and offered a supportive environment, with structured activities, groups and regular 
compact-based drug testing. HMP Pentonville 2015 
4.79 Drug recovery or drug-free wings exist in many establishments, although we found that many 
were not actually fulfilling this brief. Outcomes on many units were adversely affected by a 
poor regime, excessive numbers of residents who were on the unit for operational reasons 
and not interested in recovery, and inconsistent staffing. In four of the 61 adult prison 
inspections published between April 2014 and August 2015, we made recommendations that 
only those in recovery should be housed on these units, and in six that they should be staffed 
by consistent, specially trained and selected officers. Prisoners we interviewed for this 
thematic inspection were generally positive about the residential-based support on offer in 
their prison. They said that the staff there better understood the phenomenon of addiction 
and the difficulties of managing their problems.  
4.80 Compact-based drug testing24 can be useful evidence of engagement, contribute positively to 
prisoners’ recovery and be an effective motivator for abstinence in drug recovery wings and 
drug therapeutic communities. However, we have observed, that, although it is a positive 
tool when it is used, it is not widely available, owing to cost.   
4.81 The lack of dedicated drug recovery units impeded outcomes in some establishments, 
whereby those that achieved abstinence struggled to maintain this in a normal wing 
environment. Prisoners we interviewed said that there was pressure to take drugs on the 
main wings as they were more widely available there, and some struggled not to use illicit 
substances if they had to share a cell with someone who used drugs regularly. Some alleged 
that individuals who had successfully become drug free were then targeted by dealers 
because they were most susceptible. In several inspection reports published between April 
2014 and August 2015, we recommended that drug recovery wings should be developed to 
support prisoners in their recovery.   
Peer support 
4.82 Mutual aid in the form of peer-led social, emotional and informational support is recognised 
as a key aspect of effective psychosocial drug treatment, both in prison and the community 
(ACMD, 2013; Public Health England, 2013b). This includes 12-step-based interventions such 
as Narcotics Anonymous (NA) and self-management and recovery training (SMART) 
recovery.  
4.83 NOMS has identified that a feature common to women who have successfully desisted from 
crime is that they develop a positive social identity, often as a result of activities that have 
exposed them to positive pro-social peers and allowed them to do good for the community 
(NOMS, 2015e). This could include becoming and/or working with a peer supporter, and is 
likely also to be true for some men.  
4.84 HMI Prisons inspections during 2014–15 found that access to mutual aid groups such as NA 
and to well-trained and supervised peer supporters was good in many adult prisons. Some 
prisoners interviewed for this thematic inspection said that these services were not available 
when they wanted them, and in one establishment NA groups had been discontinued and 
replaced with other support which prisoners considered to be inferior. In prison inspection 
                                                                                                                                                                                     
24 Compact-based drug testing is voluntary drug testing carried out with the informed consent of the prisoner within a 
clear behaviour compact. A positive result may lead to removal from a drug recovery or drug-free community. 
 Section 4. Service responses 
62 Changing patterns of substance misuse in adult prisons and service responses 
reports published between April 2014 and August 2015, we found access to peer support to 
be either lacking or too limited in a significant minority of establishments. In one, prison peer 
supporters were not always available because they were not unlocked for long enough – 
again, owing to problems with staffing and reduced time out of cell under the prison core 
day. Prisoners valued peer support highly and reported it to be beneficial.  
 
Peer support services were integral to the substance misuse provision. Eight well-trained and supervised peer 
supporters co-facilitated groups and a daily drop-in session, and also provided ad hoc support on the huts. 
Following low attendance at Spice and legal high sessions run by DART workers, the group became peer led 
and engagement increased significantly. DART workers and peer supporters had provided drug awareness 
sessions for young adult prisoners at Aylesbury prison that had been well received. The peer supporters we 
spoke to were positive about the impact of their role on their personal recovery as well as the support they 
gave others. Peer supporters also ran weekly Narcotics Anonymous and Gamblers Anonymous groups, and an 
external facilitator ran a weekly Alcoholics Anonymous group. HMP Springhill 2014 
 
Each of the 13 peer supporters undertook an Open College Network level 2 qualification in substance 
awareness and peer mentoring. They had benefited from the effective recovery programmes in place, and 
could now pass on what they had learned. They received support from a dedicated worker, who ran a weekly 
mentors’ support group and regular one-to-one supervision. HMP Belmarsh 2015 
Family involvement in support 
4.85 Many prisoners have family and friends in the community, and some prisoners we 
interviewed for this thematic inspection cited family as sources of support. Evidence suggests 
that family and social networks are influential both during addiction and in recovery (Copello 
and Orford, 2002; Lander et al., 2013). Prisoners’ family and friends can be targeted for 
education to harness their effectiveness in supporting the prisoner in recovery, and also to 
help them to cope with the effects of the prisoner’s drug use. This could include training 
them to use the opiate antidote naloxone, which could help to reduce the number of fatal 
drug overdoses in the community. It could also be an opportunity to support some visiting 
family and friends into treatment themselves. Only a few substance misuse services we have 
inspected offered any structured family support, which was a wasted opportunity to improve 
outcomes. In some prisons, families are invited to support a prisoner graduating from 
treatment programmes, which is a positive initiative. Prisoners and staff we interviewed in 
the women’s prison for this thematic inspection spoke positively about the family support 
offered to those with substance misuse problems.  
 
Support was provided to prisoners and their families by the in-prison family recovery worker. Since the start of 
the service in November 2013, 70 prisoners and 27 family members had engaged with the service… The 
family recovery service improved the potential for successful resettlement and family reintegration of prisoners 
who were substance misusers. HMP Bedford 2015 
 
Prisoners also had access to the national Addaction network of community-based substance use support 
services, and an in-house support helpline was available for families… The Addaction in-house telephone 
helpline service offered support and information to friends and families affected by prisoners' drug and 
alcohol misuse. HMP North Sea Camp 2014 
 
An organisation called Families and Loved ones accessing Mutual and Emotional Support (FLAMES) held 
bimonthly events, where families of residents in the therapeutic community could attend the establishment for 
structured visits and link up with mutual aid efforts in their communities. HMP Garth 2014 
4.86 However, as already referred to, family and friends can also be a potential route for drug 
supply and may themselves be pressured into bringing drugs into the prison. Family and 
friends may be reluctant to report this to the authorities, and we also found little 
appropriate assistance available for them. 
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Drug misuse and treatment in Wales 
 
There are recognised variations in drug misuse between England and Wales, along with differences in 
the treatment systems available. In 2013–14, higher levels of cannabis, amphetamine and hallucinogen 
use were reported in Wales but lower levels of powder cocaine and ecstasy than in England, 
according to a profile of Welsh substance misuse (Smith and Emmerson, 2014).  
 
Evidence from HMI Prisons inspections suggested that there was a smaller problem with Spice in 
Welsh prisons compared with English prisons, although it was beginning to emerge during our 
inspection of HMP Swansea in 2014. Prisoners in the Welsh prison interviewed for this thematic 
inspection said that they had either never seen Spice or that they had seen only a few people using it. 
However, as we reported to the National Assembly for Wales Health and Social Care Committee in 
October 2014, as the use of NPS gains momentum in Welsh communities, it can be predicted with 
some confidence that Welsh prisons will see a rise in the incidence of NPS misuse. 
 
There are five prisons in Wales. HMPs Swansea and Cardiff have a local function. HMP Parc is a 
category C resettlement/training prison, with a small remand function. HMP Usk is a category C 
prison combined with HMP Prescoed, which has a category D function. A sixth prison is being built 
at Wrexham in North Wales. We compared the key findings from our most recent inspection 
surveys at each of these prisons with those from all English men’s prisons inspected between April 
2013 and August 2015. Figure 11 provides a comparison between prisoners in Welsh prisons and 
those in English prisons, looking at some key questions from the main inspection survey. 
 
Figure 11: A comparison between the responses of prisoners in Welsh prisons and those 
in English prisons (N=16,196) 
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At the time they were inspected, all of the Welsh prisons had random MDT rates that were lower 
than in comparator prisons in England.  
 
Drug treatment in Wales is organised differently to that in England. IDTS has not been funded and 
implemented in Wales. Each prison provides psychosocial and clinical support for substance misuse. 
Prisoners who arrive on a current community prescription of OST are generally maintained, 
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although, in our most recent inspections, the three prisons with a local function varied in the 
duration and nature of treatment offered. However, the main difference between English and Welsh 
prisons is that, in Wales, those arriving from the community who are addicted to opiates but not 
engaged with community treatment are not automatically offered OST in the form of methadone or 
buprenorphine on the day of arrival. Instead, a withdrawal programme, using a non-opiate 
medication, is usually offered to this group. No distinction is made between remand and sentenced 
prisoners. It is therefore not uncommon for an opiate-dependent prisoner to be remanded for 2–3 
weeks, withdrawn from opiates (regardless of their own wishes or intent to stop using drugs), and 
then returned to court and subsequently released having lost all physical tolerance to the drug. If that 
prisoner then uses opiates on release, their risk of overdose is extremely high.  
 
OST is a recognised incentive to encourage people dependent on illicit opiates into treatment. In 
Wales, the incentive for those who arrive dependent on illicit opiates to engage in treatment is 
reduced and there is an increased market for illicit drugs, as those going to prison know that they 
will not get OST. In our view, this provides a considerably less safe service for those held in prisons 
in Wales compared with those held in England, as indicated in Figure 11. The disparity is increased 
because a large number of offenders from North Wales, and all female offenders, are housed in 
prisons in England as there are no prison facilities in North Wales and none at all for female 
prisoners in Wales, and they receive very different treatment. When the new North Wales prison 
opens, it will accept prisoners from England as well as Wales, which will mean that prisoners from 
each nation will receive unequal treatment, depending on where they are held. This difference in 
treatment is also likely to have an impact on the rates of reoffending and return to problematic drug 
use on release. Figure 12 provides a comparison between the survey responses of prisoners in 
Welsh prisons and in English prisons concerning the support they received for their drug use.  
 
Figure 12: A comparison between the responses of prisoners in Welsh prisons and those 
in English prisons concerning the support they received for their drug use (N=16,196) 
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Although we found some good psychosocial work being conducted in HMP Cardiff (2013), it was 
poorly integrated with clinical treatment. In HMP Swansea, there was also poor integration of clinical 
support with psychosocial interventions. The psychosocial team was understaffed and so could do 
little more than conduct initial assessments and brief interventions. Officers on the drug recovery 
wing who had been trained to deliver group-work programmes were so frequently redeployed to 
other duties that they had ceased all programme delivery. In HMP/YOI Parc (2013), the picture was 
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better, with the psychosocial service providing a similar package of options to those found in English 
prisons.  
 
As already stated, there are no women’s prisons in Wales, and women’s prison in England cover very 
large catchment areas. Women from Wales are held in English prisons, which makes it difficult to put 
effective resettlement plans in place. Commissioners interviewed for this thematic inspection 
confirmed that this presented particular problems.   
 
The introduction of the Wales Integrated Offender Intervention Service (IOIS), which has a remit to 
reduce reoffending, has improved post-release support for prisoners with substance misuse 
problems.  
 
There were plans to create further integration between the substance misuse service and the OMU through 
substance misuse offender supervisors. There were strong links with IOIS providers at strategic and 
operational level (the head of community engagement led the drug strategy and was responsible for 
community IOISs), and prisoners could access designated prison link workers from South, West and North 
Wales who regularly attended and were able to meet those due for release at the gate. HMP/YOI Parc 
2013 
Resettlement and ‘through-the-gate’ support 
4.87 Prisoners are at risk of relapsing into drug use, increasing their drug use and reoffending, on 
release. Relapse into, or increased levels of, drug use post-release presents serious risks of 
physical harm to individuals. In 2012, the PPO highlighted an increase in drug-related deaths 
among newly released prisoners – most of whom were found to be using diverted 
prescription medicines (PPO, 2012b). It recommended that staff at approved premises be 
made aware of the dangers of both mixed drug and methadone toxicity and to ensure that 
medication administration is supervised to reduce the opportunity for the trade in 
prescription drugs. An average of two deaths a day (765) were registered in England and 
Wales in 2013, for which heroin or morphine were mentioned on the death certificate, an 
increase of 32% on 2012 (Office for National Statistics, 2014).  
4.88 The reoffending rate for those released from custody between April 2011 and March 2012 
was 45.8%, and varied by age and gender, with a higher rate for men and young people. A 
Ministry of Justice review of evidence on reoffending from 2014 highlighted that reconviction 
rates were higher among prisoners who had used drugs in the month before going into 
custody (MOJ, 2013). 
4.89 The health risks associated with drug use on exit from custody and high reoffending rates 
alike carry high costs for society generally, emphasising the key role of effective resettlement 
activity. 
Resettlement 
4.90 Effective resettlement from prison to the community involves several strands, including 
support with:  
 Accommodation 
 Education, training and employment 
 Changing attitudes, thinking and behaviour 
 The maintenance of family ties  
 Finance, benefit and debt  
 Continuity of treatment for all physical, mental and substance misuse issues 
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 Individualised health promotion advice to reduce the risk of harm, including drug 
overdose, blood-borne viruses and sexually transmitted infections. 
4.91 Considerable changes to resettlement planning and provision were introduced in April 2015 
as a result of the Offender Rehabilitation Act 2014. The Act grants powers to community 
rehabilitation companies (CRCs) to make drug tests of adult offenders released on licence 
compulsory and require them to attend appointments designed to address their substance 
misuse. It is too early to comment on the impact of these changes. 
Accessing treatment on release 
4.92 A DrugScope State of the Sector survey (2015b) revealed the pressures affecting community 
drug services. Half of those who responded reported a range of challenges, including reduced 
funding and staffing, difficulties in accessing support services (including housing), support for 
older clients, mental health services and employment. The constant cycle and churn of local 
commissioning and recommissioning was also reported to have had an impact. This is likely 
to affect the ability of services to support their clients, including ex-prisoners. Some 
commissioners we interviewed for this thematic inspection said that a reduction in budgets 
was resulting in more innovative and integrated treatment models. Public Health England has 
stressed the importance of continuing current levels of funding to address drug and alcohol 
misuse owing to its positive impact on health and social outcomes, including offending (PHE, 
2015a). 
4.93 Prison substance misuse services are primarily commissioned by NHS England, and 
community services are commissioned by Public Health England. Our interviews with 
commissioners indicated that there was little joint working, which could result in a disjointed 
approach.  
4.94 Continuity of, or access to, drug treatment on release is an important aspect of 
resettlement. Public Health England figures indicate that prisons were responsible for 9% of 
referrals into community drug treatment in 2013–14 (Public Health England 2014a). National 
Drug Treatment Monitoring System data indicate that a high proportion of prisoners 
referred into community opiate substitute prescribing do not attend their appointments 
post-release, with only 24% of those referred to community drug services attending the 
treatment service within three weeks of release. Our interviews with prisoners suggested 
that several factors were responsible for this. Some admitted that attending treatment would 
not be their first priority on release, and several thought that they would lack the willpower 
either to make appointments or to turn up. Others did not find service locations practical – 
for example, if they had employment in a different area. Some prisons make the 
arrangements for prisoners to attend – either by arranging for the agency to collect 
prisoners from the prison gate and take them to their appointments or providing transport 
for them to attend their first appointment, which increases engagement with services post-
release.   
4.95 Commissioners we spoke to for this thematic inspection said that the number of released 
prisoners attending community services for support for either NPS or illicit medication 
issues is low. This may be because released prisoners do not see NPS or illicit medication 
use as a problem, or their perceptions that community services will be unable to help or that 
any drug problem will have been resolved on release.   
4.96 When interviewed for this thematic inspection, most health care commissioners noted that, 
while there were occasional issues with sudden releases from court or on bail, overall, 
liaison from prisons before release was effective..  
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4.97 Some prisoners who successfully withdraw from opiates in prison and then return to the 
same social circumstances on release that contributed to their previous drug use are at high 
risk of relapse. A planned introduction of OST with methadone or buprenorphine before 
release, in consultation with community services, can be a positive intervention alongside 
other psychosocial support, as it means that the prisoner will have increased tolerance on 
release and be at a lower risk of an opiate overdose. This intervention is not appropriate for 
all and should only occur following multidisciplinary input, including community services. 
4.98 While every attempt should be made to reduce the likelihood that released prisoners will 
use drugs on release, some released prisoners will return to drug use and they are at an 
increased risk of overdose.  
4.99 Take-home naloxone is an important and cost-effective harm-reduction initiative which 
enables opiate drug users and their families to provide a timely overdose intervention that 
can save lives, following appropriate training (ACMD, 2012). HMPs Cardiff, Swansea and Parc 
all participate in the national take-home naloxone programme. Public Health England has 
published guidance on its use (2015b). In 2005, naloxone was added to the list of injectable 
medicines that can be used legally by anyone to save a life in an emergency, so can be held by 
a family member or friend (Medicines for Human Use Order, 2005). To achieve the best 
impact on overdose rates, as many people as possible should be trained to use naloxone. A 
change in medicine regulations in October 2015 has allowed naloxone to be issued without a 
prescription, which may increase its use. Most English prisons we inspect do not currently 
offer this service; however, training motivated prisoners and their families could be a very 
valuable harm reduction initiative to reduce opiate overdoses in the community. We 
highlighted the participation of HMP Bristol in the national pilot scheme in England as an 
example of good practice. 
 
The prison continued to participate in a national naloxone pilot scheme, training prisoners to treat opiate 
overdose on release. The ‘N-ALIVe’ study had been recruiting participants since January 2013 and 340 
prisoners had joined in the study. HMP Bristol 2014 
4.100 Engagement in community treatment on release can be improved by having continuity of a 
case worker or services between the prison and the community.  
 
…the same providers were used in prison and in the community; this offered joined-up continuation of care 
on release. Assessments and recovery plans were shared with drug intervention programme teams, and 
designated prison link workers were based at the establishment. New developments included a pilot ‘through-
the-gate’ reception scheme based at the community engagement centre next to the prison … and pre-release 
drug testing. Prisoners could be met at the gate by recovery mentors on release. HMP Preston 2014 
 
Good joint working between departments took place, the drug and alcohol recovery team contributed to 
sentence planning, release plans were good and women were consistently given harm reduction information. 
The opiate-blocker naloxone was available pre-release. Throughcare services were also provided to women 
with alcohol problems. Styal was a pilot site for through-the-gate services… Fifty-six women were actively 
involved with the service, including 18 who received follow-up in the community. Strong links had been made 
with community women’s centres and the project included peer mentor support. Weekly case management 
meetings with community partners facilitated ongoing care coordination and files demonstrated good-quality 
post-release work. HMP Styal 2014 
 
Outcomes for prisoners with drug and alcohol problems were excellent. [The drug treatment service provider] 
provided drug intervention programme services in the North West region, helping to maintain continuity of 
care where prisoners needed substance use support on release. The prison was also involved with the 
Gateways resettlement scheme, which offered a wide range of interventions, including post-release mentoring 
support and abstinence recovery housing. Gateways, in partnership with the Work Company, a non-profit 
employment and recruitment organisation, delivered a service preparing substance users to access 
employment, training and education following a programme of one-to-one mentoring and up to 12 weeks’ 
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community support post-release. Gateways also ran a take-home naloxone scheme that trained prisoners with 
a history and continued risk of injecting drug use to apply an opiate overdose antidote kit. The kits were 
issued at the point of release. HMP Lancaster Farms 2015  
 
Resettlement opportunities for prisoners with substance misuse needs who were residents of Hampshire and 
Dorset were good, mainly because of the recent appointment of a full-time community integration and 
support worker. A wide range of services was delivered, including arranging gate pick-ups, housing, 
rehabilitation centre funding, community treatment, arranging recovery champion visits to the prison and 
developing links with regional drug intervention programme and drug, alcohol and assessment teams. HMP 
Winchester 2014 
Accommodation and training needs  
4.101 The effectiveness of the support provided by prisons is increased if all the risk factors are 
addressed before the prisoner is released, including employment, housing, domestic violence 
and issues related to prostitution. The North-West ‘Through The Gate Substance Misuse 
Services’ pilot provides comprehensive resettlement support for some prisoners with 
substance misuse issues, and some of the services we inspected that are part of this pilot 
were very promising. 
The North-West ‘Through the Gate Substance Misuse Services’ pilot 
The ‘Through the Gate Substance Misuse Services’ pilot project at 10 North-West prisons is 
designed to test a comprehensive end-to-end approach to tackling addiction by improving the 
identification of drug misusers and increasing access into treatment. This will provide greater levels 
of self-motivation and engagement with treatment, and continuity of care through the gate for drug 
misusers entering, transferring between and leaving prisons. It includes anonymous drug testing on 
arrival into and on leaving the prison, and since December 2014 the testing panel has incorporated 
anonymous testing of Spice, prescription-only drugs and a wider selection of drugs than MDT as part 
of public health monitoring on prevalence. All prison drug seizures have also been submitted for 
analysis as part of the Home Office ‘forensic early warning system’ (FEWS) (NOMS, 2014b). The 
pilot is currently being evaluated. 
4.102 Prisoners interviewed for this thematic inspection told us how important accommodation 
and other practical resettlement services were to prevent relapse. Since May 2015, CRCs 
have taken over most practical resettlement services and need to work closely with 
substance misuse services to provide the range of support necessary to reduce the likelihood 
of relapse. It is too early to assess the effectiveness of CRCs. 
4.103 At HMP The Mount (2015), we found the following good practice in relation to resettlement 
planning, which also made good use of peer supporters to support prisoners before release. 
 
The RAPt team also organised a project called ‘group aftercare peer support’ (GAPS). Peer supporters 
facilitated GAPS groups for one session a week for 12 weeks for prisoners with substance use issues who 
were nearing release. Visiting speakers from community agencies gave presentations promoting education, 
training and employment, housing and recovery-based services for these prisoners. Participants then drew up 
their own resettlement action plans, which were peer reviewed by the group. The finished action plan was 
then presented to the OMU with any additional necessary input from the RAPt resettlement worker. HMP 
The Mount 2015 
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Section 5. Appendices 
Appendix I: Methodology 
5.1 This thematic inspection looked at substance misuse within the adult prison estate (including 
young adults). It drew on a total 61 HMI Prisons inspections of prisons published between 
April 2014 and August 201525 and, where it was helpful, on some earlier inspections. In 
addition to the information gathered from the inspection reports themselves, the collective 
survey responses over this period were also analysed. The analysis of inspection reports and 
survey responses included the following establishment types: 
 
Type of prison Number of 
prisons 
Number of 
respondents  
Local prisons 25 4,479 
Category B training prisons 4 715 
Category C training prisons 14 2,458 
High secure prisons 3 489 
Young adult prisons 5 866 
Open prisons 5 717 
Women’s prisons 7 978 
Total 6326 10,702 
 
5.2 Additional fieldwork was conducted in eight prisons, as described below.  
5.3 HMI Prisons inspects all aspects of prison life against our expectations (HM Inspectorate of 
Prisons Expectations 2012, 2014). When inspecting substance misuse services, a specialist 
inspector specifically looks at: 
 
 Supply reduction strategic approach and practices 
 Clinical services, including stabilisation, planned reduction and maintenance, for prisoners 
with drug addiction 
 Prescribing of opiate substitution treatment 
 Safety of drug administration, including opportunities for medication diversion 
 Psychosocial services, including specialist drug recovery wings  
 Mental health support for those with a dual diagnosis 
 Continuity of support for prisoners on release and 
 How well all the above are integrated. 
 
                                                                                                                                                                                     
25 When more than one inspection had taken place at an establishment, only the most recent inspection report was 
included.  
26 Two surveys were carried out at two establishments during this period to reflect their dual functions. HMP Hewell has 
an open function alongside its main local function, and HMP Winchester has a separate category C unit alongside its main 
local function.   
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5.4 The substance misuse inspector will also link in with other inspectors where the areas of 
inspection overlap and have a positive or negative impact on levels of substance misuse and 
support services, including security, health services, purposeful activity and safer custody. 
Additional analysis of Welsh prisons 
5.5 In addition to the analysis of survey responses published in inspection reports between April 
2014 and August 2015, the responses of prisoners in Welsh prisons were compared with 
those of prisoners in English prisons. This analysis covers prison inspection reports published 
between April 2013 and August 2015, drawing on 817 respondents in five Welsh prisons and 
15,379 respondents in 93 English prisons. 
Additional fieldwork in prisons 
5.6 Fieldwork was conducted in a total of eight establishments holding adult offenders between 
June and November 2014. Additional information collected did not form part of the main 
inspection judgement. 
5.7 Prisons were selected to include a range of the different functional types of establishment 
and ensure that different regional areas were also included: two local prisons, a category C 
trainer prison, an open prison, a high secure prison, a young offender institution, a women’s 
prison and a prison in Wales were included.  
5.8 Fieldwork in prisons comprised the following steps. 
A survey of prisoners 
5.9 A short questionnaire was administered to a representative sample of prisoners at the same 
time as the regular HMI Prisons prisoner survey conducted in advance of every inspection.  
5.10 Surveys were carried out to government social research standards. Using a robust statistical 
formula, we calculated the sample size required to ensure that our survey findings reflected 
the experiences of the entire population of the establishment. Respondents were then 
randomly selected from a P-Nomis (electronic case notes) prisoner population printout, 
using a stratified systematic sampling method. We also ensured that the proportion of black 
and minority ethnic prisoners in the sample reflected the proportion in the prison as a 
whole. 
5.11 The questionnaire included questions on: 
 
 Drug use in the two months before entering prison 
 Drug use within their current prison 
 The perceived availability and sources of both illicit drugs and diverted medication. 
5.12 The questionnaire also provided prisoners with the opportunity to opt in to speak to a 
researcher as part of the fieldwork. A total of 1,218 surveys were analysed as part of this 
report; these were distributed as follows: 
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Type of prison Number of 
prisons 
Number of 
respondents  
Local prisons27 3 493 
Category C training prisons 1 175 
High secure prisons 1 139 
Young adult prisons 1 137 
Open prisons 1 141 
Women’s prisons 1 133 
Total 8 1,218 
 
Prisoner interviews 
5.13 Semi-structured confidential interviews were conducted with a total of 85 prisoners across 
eight establishments. Prisoners who consented to take part in an interview were sampled to 
ensure that a variety of experience was captured, including drugs used in the community and 
those used in prisons.  
5.14 Prisoners were asked about: 
 
 Previous misuse of illicit drugs and medication in the community 
 Use of illicit drugs and medication in their current prison 
 Sources of drugs and perceived availability of illicit drugs and medication within their 
current prison 
 Awareness and experiences of substance misuse services within their current prison, and 
their future support needs, both in their current prison and on release. 
Staff interviews 
5.15 Semi-structured interviews were conducted with a total of 34 members of staff across eight 
establishments. These covered: 
 
 Knowledge of substance misuse outside the prison  
 Substance misuse trends in the prison and motivations for use 
 Awareness of the sources of drugs and problems arising from substance misuse in prison 
 Responses to substance misuse, in terms of both support services and supply reduction 
measures.  
Community fieldwork 
5.16 Semi-structured interviews were conducted with 13 local authority commissioners of 
services in the English prisons where our fieldwork was conducted, five commissioners of 
services for other prisons, and six NHS England commissioners across England. The aim of 
                                                                                                                                                                                     
27 This includes one local prison in Wales.  
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these interviews was to gain a wider understanding of the presentation and treatment needs 
of those in prison, and of offenders and ex-offenders in contact with community services. 
We were unable to speak to a commissioner from Wales. We also spoke to four substance 
misuse public health leads.  
5.17 Interviews covered the following areas: 
 
 The needs of prisoners in prison and on release into the community 
 Local substance misuse trends and needs analysis 
 Local substance misuse service commissioning  
 Connections between commissioned substance misuse services and probation and 
mental health services. 
 
 
Section 5 – Appendix II: Terminology 
 Changing patterns of substance misuse in adult prisons and service responses 73 
Appendix II: Terminology 
 
Term Definition 
Adjudications Disciplinary hearings within prisons 
Assisted withdrawal Previously known as detoxification. Main goal of treatment is to support 
the individual who is physically dependent on a substance(s) to come off it 
safely, with reduced adverse physical symptoms, using an alternative 
licensed drug within a planned regime; for example, a reducing dose of 
methadone may be used to assist someone to come off heroin. For most 
people, this can be done in the community but some people may need 
close monitoring and support, so will do this in a hospital setting  
Benzodiazepines A group of tranquilliser (see below) medications which have been used to 
treat: anxiety, agitation and restlessness; epileptic seizures/fits; mania; 
alcohol withdrawal; and sleeping problems. These include diazepam, 
chlordiazepoxide, clonazepam, lorazepam. Users may find that they are 
dependent on the drug and experience unpleasant withdrawal symptoms 
– nausea, tremors, panic attacks and depression 
Black Mamba A form of synthetic cannabis 
Buprenorphine Medication used to treat opioid dependence. Also known as Subutex and 
Suboxone in the UK. In lower doses, it is used for pain relief as Temgesic 
Cannabis Naturally occurring drug found in cannabis plants. Can make users feel 
happy and relaxed, and cause hallucinations, anxiety, paranoia, memory 
loss and loss of concentration 
Class A, B and C The classification of drugs based on their capacity for harm, as per the 
Misuse of Drugs Act 1971 (A = most harmful and carries the harshest 
punishments) 
Cocaine A strong, short-acting stimulant drug – comes in powder form  
Codeine An opiate drug used for pain relief 
Crack cocaine (‘crack’) An intense, short-acting stimulant drug produced from cocaine  
Dependence A cluster of physical, behavioural and psychological phenomena that may 
develop after repeated use of a substance. It typically includes a strong 
desire to take a particular substance, impaired control over its use, 
persistent use despite harmful consequences, a higher priority given to 
drug use than other activities and responsibilities, increased tolerance and 
a physical withdrawal reaction when the drug is discontinued. A diagnosis 
of dependence is made if three or more of six specified criteria have been 
experienced within a year. Dependence may relate to a single substance 
(e.g. tobacco, alcohol, heroin), a class of substances (e.g. opioids) or a 
wider range of different substances (e.g. alcohol, diazepam and heroin) 
Depressants Drugs causing a decreased awareness of surroundings, decreased 
alertness, a narcotic effect and blunted emotions (Fazel et al., 2006)  
Dual diagnosis The co-existence of mental health and substance misuse problems 
Ecstasy Also known by chemical name, 3,4-methylenedioxy-methamphetamine 
(MDMA). Makes the user energised, happy and awake for hours 
Gabapentin Prescription-only medication used to treat epilepsy and pain from 
damaged nerve tissue. It can enhance the euphoric effects of opiate drugs 
(with increased health risks) 
Hallucinogenic [drugs] Drugs that distort perceptions of reality, either found in plants and 
mushrooms (or their extracts) or man-made, such as lysergic acid 
diethylamide (LSD) 
Heroin An opiate drug (also called diamorphine)  
HMI Prisons Her Majesty’s Inspectorate of Prisons 
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IDTS Integrated drug treatment system – joint initiative by the Department of 
Health, Home Office, Ministry of Justice and National Offender 
Management Service to provide continuity of care for offenders between 
prison(s) and the community 
Illicit/illegal [drugs] ‘Illicit’ means ‘forbidden by law, rules or custom’, whereas ‘illegal’ means 
‘forbidden by law (especially criminal law)’ (www.Oxforddictionaries.com; 
last accessed 18 March 2014) 
Illicit drug classification Under the Misuse of Drugs Act 1971, illegal drugs are placed into one of 
three classes – A, B or C – broadly based on the harms they cause either 
to the user or to society when they are misused. Drugs controlled under 
the Misuse of Drugs Act are illegal to have, produce, give away or sell. 
Class A drugs are considered likely to cause the greatest harm, and 
attract the severest penalties related to offences involving these drugs. 
Class A drugs: Crack cocaine, cocaine, ecstasy (MDMA), heroin, LSD, 
magic mushrooms, methadone, methamphetamine (crystal meth). 
Penalty for possession: Up to seven years in prison, an unlimited fine 
or both. Penalty for supply and production: Up to life in prison, an 
unlimited fine or both. Class B drugs: Amphetamines, barbiturates, 
cannabis, codeine, ketamine, methylphenidate (Ritalin), specified synthetic 
cannabinoids, synthetic cathinones (e.g. mephedrone, methoxetamine). 
Penalty for possession: Up to five years in prison, an unlimited fine or 
both. Penalty for supply and production: Up to 14 years in prison, an 
unlimited fine or both. Class C drugs: Anabolic steroids, benzodiazepines 
(e.g. diazepam), gamma-hydroxybutyrate (GHB), gamma-butyrolactone 
(GBL), piperazines (BZP), khat. Penalty for possession: Up to two 
years in prison, an unlimited fine or both (except anabolic steroids – it is 
not an offence to possess them for personal use). Penalty for supply 
and production: Up to 14 years in prison, an unlimited fine or both. 
Temporary class drugs: The government can ban new drugs for one 
year under a ‘temporary banning order’ while they decide how the drugs 
should be classified. Five compounds relating to methylphenidate, a Class 
B drug, were banned from 10 April 2015. Penalty for possession: 
None, but police can take away a suspected temporary class drug. 
Penalty for supply and production: Up to 14 years in prison, an 
unlimited fine or both 
IP ‘In-possession’ – when a prisoner keeps their prescribed medication in 
their cell 
Legal ‘highs’ Substances that are not prescribed or illegal but which give users a ‘high’ 
similar to that induced by those types of substances. They are not 
controlled under the Misuse of Drugs Act, but it is considered illegal 
under current medicines legislation to sell, supply or advertise them for 
‘human consumption’. To get around this, sellers refer to them as 
‘research chemicals’, ‘plant food’, ‘bath crystals’ or ‘pond cleaner’. 
Generally, the term ‘legal high’ is now largely avoided as it can give a false 
impression of safety and the testing of so-called legal highs has shown that 
many contain illegal substances 
Maintenance Prescribing a stable dose of methadone or buprenorphine for an individual 
with a physical dependence on opiates over a sustained period, often 
while they address underlying social, physical or mental health issues and 
with psychosocial support 
MDT Mandatory drug testing – to identify and measure (and therefore tackle) 
illicit drug taking in prisons 
Methadone A synthetic opiate drug used to treat opioid dependence since the mid-
1960s. It can be given orally once daily 
Methcathinone  A stimulant drug 
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Mephedrone Also known as 4-methylmethcathinone (4-MMC) or 4-methylephedrone, 
this is a synthetic stimulant drug of the amphetamine and cathinone 
classes. Slang names include drone, M-CAT, White Magic and meow 
meow. It is chemically similar to the cathinone compounds found in the 
khat plant of eastern Africa. It comes in the form of tablets or a powder, 
which users can swallow, snort or inject, producing similar effects to 
MDMA, amphetamines and cocaine. It was first synthesised in 1929 but 
was rediscovered in 2003; by 2006, it was reported to be available for 
sale on the internet and was very prevalent in the UK by 2010. Synthetic 
cathinones, including mephedrone, have been controlled as Class B 
substances since 2010. Mephedrone has been the most prevalent of the 
NPS reported but still represents a very small proportion of illicit drug 
use and appears to have reduced in popularity in many areas since its 
peak in 2010. The NPS Review Expert Panel September 2014 reported 
that it is likely that mephedrone use has fallen owing to a number of 
factors, such as control, a growing awareness of harms, and increased 
purity and availability of drugs such as ecstasy 
Morphine See ‘Opiates’ 
Narcotics  Psychoactive compounds with sleep-inducing effects, but now commonly 
refers to opioids or, more generally, illegal substances 
NDTMS National Drug Treatment Monitoring System – collection, reporting and 
consolidation of drug treatment data to understand outcomes 
NTA National Treatment Agency for Substance Misuse. Now part of Public 
Health England 
OASys Offender assessment system – used by the Prison Service and Probation 
Service to measure the risks and needs of criminal offenders under their 
supervision 
Opiates; opioids Drugs with effects similar to opium. They stimulate opioid receptors in 
the brain and nervous system. They are used for pain relief and include 
codeine, morphine, buprenorphine and diamorphine (heroin) but can be 
used to ‘get high’ and can easily become addictive 
OST Opioid substitution therapy/treatment – the medical process of 
substituting an illegal opioid drug (e.g. heroin) with a less ‘euphoric’ 
opioid, under medical supervision 
PPO Prisons and Probation Ombudsman – investigates complaints from 
prisoners, people on probation and immigration removal centre detainees 
Pregabalin Prescription-only drug to treat epilepsy, pain from damage to nerve 
tissue, and anxiety 
Psychoactive substance A chemical substance that acts on the central nervous system to alter 
brain function – perception, mood, consciousness, cognition and 
behaviour 
Psychosocial support Refers to a wide range of support interventions that may be offered to an 
individual to address physical and psychological dependence in addition to 
any prescribing support. It may include support at different levels of 
intensity, reflecting the severity of the disorder or previous experience of 
treatment. It can be delivered by staff or peers as one-to-one or group 
sessions. It also often includes practical support and strategies to address 
social needs, increase confidence and build a positive social support 
network  
PHE Public Health England. 
Security categorisation in England 
and Wales 
Sentenced male adult prisoners aged 21 or over are given a security 
category. These categories are based on a combination of factors, 
including the type of crime, length of sentence, likelihood of escape and 
danger to the public if they should escape. The categorisation can go up 
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or down during a sentence, based on assessed risk. There are four 
categories – A, B, C and D, with A being the highest category and D the 
lowest. The level of security in a prison is directly linked to the category 
of prisoner that the prison can hold, so category D (also known as 
‘open’) prisons have little physical security such as perimeter walls and 
razor wire. Open prisons are an important part of reintegration into the 
community. 
Sentenced women are classified into three main categories: restricted 
status, which is similar to category A for men; closed, which is for women 
who do not require restricted status but for whom escape needs to be 
very difficult; and open, which is similar to category D for men. 
Additionally, women can be exceptionally categorised as category A.  
Sentenced young adult males (18–20) have the same categories as women 
Sedatives See ‘Tranquillisers’ 
Sleepers Tablets taken to induce sleep 
Spice A popular form of synthetic cannabis 
Stabilisation Initial phase of drug treatment, where the focus is on getting the client 
stable on a suitable dose of opiate substitution treatment (methadone or 
buprenorphine) that keeps them engaged in treatment without the need 
to supplement with other drugs. It includes psychosocial support 
Stimulants Include methylone, mephedrone and methcathinone 
Strip-search A search involving the removal of more than outer clothing 
Suboxone See ‘Buprenorphine’ 
Subutex See ‘Buprenorphine’ 
Synthetic cannabis Chemicals made to act like the active part of cannabis, a substance called 
tetrahydrocannabinol (THC), but are often much stronger. Their short- 
and long-term adverse effects are not fully known but experts predict that 
they have the potential to be more harmful than cannabis. Their effects 
are likely to be similar to those of cannabis – some users will feel happy 
and relaxed, and they may get giggly, feel hunger pangs and become 
talkative; others, however, may feel ill or paranoid. Synthetic cannabinoids 
are usually sold in herbal smoking mixtures but are available as a liquid. A 
large number of the compounds are now Class B controlled substances 
and it is impossible to tell what is in the mixture unless it is analysed 
Tolerance A decrease in the effect or response to a drug that occurs with continued 
use, so that increased doses are required to achieve the effect previously 
obtained with a lower use  
Tramadol Opiate-based painkiller 
Tranquillisers Sedatives. Drugs that induce periods of calmness, relaxation and sleep, 
and are therefore used to treat anxiety and insomnia. Available on 
prescription only 
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Diverted medications 
Synthetic cannabis 
Who diverts medication? 
Some  
prisoners 
willingly sell 
their meds 
Bullies take 
meds from 
others by  
theft or threats  
Some  
prisoners fake 
symptoms to 
get meds 
Sedation 
Lack of coordination 
Depressed respiration 
Altered states of consciousness 
Gastrointestinal complaints 
Changes in blood pressure  
Changes in heart rate 
Interactions with other drugs and alcohol 
Potentiation of other drugs (increased effects) 
Tolerance and dependence 
Withdrawal e.g. anxiety, insomnia, seizures etc.  
Poly drug use - (taking 2 or more drugs 
together or sequentially) has been associated 
with deaths in custody 
sleeplessness  
boredom 
dependency 
other health 
              problems 
physical pain 
emotional pain 
anxiety 
stress 
depression 
Diverted meds are used to self-medicate:  
Destabilisation of prison 
safety through debt, 
bullying, violence,  
self-harm or  
prisoners  
seeking  
segregation  
&/or transfer  
 to avoid  
trouble 
 
 
Some prescribers may 
overreact when prisoners 
fake symptoms by  
refusing to prescribe 
medications needed  
by other prisoners  
in genuine pain 
When meds diversion  
is a problem, already  
limited officer resources  
have to be used to  
conduct searches & tests  
& supervise meds hatches 
Prescribers may be 
threatened to 
prescribe what 
prisoners want 
Which kinds of medication are 
most commonly diverted?  
tramadol, codeine  
dihydrocodeine 
co-codamol 
Opiate Analgesics 
Prison Pharmacy 
28 tablets BP 
gabapentin 
pregabalin 
 
Anti-Convulsants 
Prison Pharmacy 
28 tablets BP 
buprenorphine 
methadone 
 
Opiate Substitutes 
Prison Pharmacy 
28 tablets BP 
benzodiazepines: 
e.g. diazepam 
chlordiazepoxide 
Sedative Hypnotics 
Prison Pharmacy 
28tablets BP 
olanzapine 
quetiapine 
Anti-Psychotics 
Prison Pharmacy 
28 tablets BP 
citalopram 
mirtazepine 
 
Anti-Depressants 
Prison Pharmacy 
28 tablets BP 
How is medication diverted? 
Meds diverted in the community are smuggled in by arriving 
prisoners, visitors, prison staff, or thrown over prison walls 
Meds are 'palmed' - i.e. not swallowed during ‘see-to-take’ at 
meds hatches but are passed to another prisoner or taken 
away for later sale or use 
Meds are swallowed by prisoners at the meds hatch and then 
later regurgitated & sold or given to others 
Meds legitimately given to prisoners in possession may be 
sold or taken from them by theft or threats  
Diversion 
Smuggled 
Palmed Regurgitated 
In Possession 
What is diverted medication 
in a prison setting? 
Medication is said to have been ‘diverted’ if it is in 
the possession of, or is taken by, someone other 
than the person for whom it was prescribed; or is in 
anyone’s possession following supervised 
consumption or is outside the time-frame stipulated 
on the prescription 
Medications (meds) that are commonly diverted (or 
traded) in prisons tend to be those that treat pain 
and/or have a mood altering effect 
What are the effects  
of using diverted meds? 
Part of a broad group of drugs originally known as 
’legal highs’; and now generally referred to as New 
(or Novel) Psychoactive Substances (NPS).  
Synthetic cannabis (SC) is illicitly made to mimic 
the effects of the psychoactive ingredient of 
natural cannabis: Tetrahydrocannabinol (THC).  
SC is sprayed on to dried herbal matter or paper.  
Two specific SC products have become popular: 
‘Spice’ and ‘Black Mamba’. These two names are 
now the most commonly used generic names for 
SC. The choice of which of the two names is used 
appears to be regional, but Spice is the most 
widely used name. 
Who uses Spice? 
Regular users of other drugs 
Dependent Spice users 
Experimental Spice users 
Some have a good experience, but many do not 
Some do not know they are smoking Spice until 
the side-effects start   
Slurred speech 
Red eyes 
Sweating   
Vomiting 
Increased heart rate 
Loss of control & balance 
Psychotic episodes, paranoia 
Agitation, anxiety 
Panic attacks, amnesia 
Seizures, death 
According to the Prisons and Probation Ombudsman 
(PPO), the use of NPS including Spice, was a factor in at 
least 19 prisoner deaths between 2012 and 2014 
 
The National Offender Management Service (NOMS) has 
said that addressing the increasing use of synthetic drugs 
and the increase in violence and serious assaults linked 
to this is a key target for the Prison Service in 2015-16  
How does Spice get into prisons? 
Destabilisation of 
prison safety 
through debt, 
bullying,  
violence,  
self-harm or  
prisoners  
seeking  
segregation  
&/or transfer  
Healthcare staff are  
often called to  
medical emergencies  
when prisoners use Spice.  
This reduces healthcare 
capacity to provide care  
to other prisoners  
Spice can be smuggled into prisons by:  
 newly arriving or transferred prisoners  
 visitors  
 corrupt staff  
 
Spice  also comes over prison walls by: 
 associates of prisoners using catapults 
 and even flying drones over walls to deliver Spice  
What is synthetic cannabis? 
What are the effects of using Spice? 
Spice is normally smoked in a hand rolled cigarette 
Because of widely varying strengths of Spice, the 
effects are very unpredictable. Some prisoners make 
others try a spice batch to determine the strength 
This is called taking the ‘Spice Challenge’ or using a 
’Guinea Pig’.  
This practice is often used as a way to pay off debts 
How is Spice used? 
When multiple  
prisoners have acute 
medical symptoms, local 
community emergency 
services can be put under 
huge strain, leaving the 
community with reduced 
ambulance cover   
Whenever a prison   
has a drug  
problem, already 
limited officer 
resources have to  
be used to conduct 
searches & deal  
with violence and 
medical emergencies 
It is not detected by existing 
Mandatory Drug Tests (MDT) 
Changing ingredients makes  
its legal status uncertain  
It often smells like incense,  
which is permitted in prisons 
It only takes a small amount  
to have a large effect 
